[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 251
1. Yang GZ, Li J, Ding HY: Localized malignant myxoid anaplastic mesothelioma of the pericardium. J Clin Med Res; 2009 Jun;1(2):115-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized malignant myxoid anaplastic mesothelioma of the pericardium.
  • Primary malignant mesothelioma of the pericardium is a rare cardiac neoplasm.
  • In the paper, we describe a young male patient having no exposure history of asbestos with localized malignant myxoid mesothelioma of the pericardium.
  • The tumor displayed significant myxoid change in stroma, and anaplastic cytology, including pleomorphy, poor cohesion, prominent nuclei, with high mitoses, which led to difficulty in diagnosis.
  • KEYWORDS: Myxoid mesothelioma; Anaplastic; Diagnosis; Immunohistochemistry; Prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22505977.001).
  • [ISSN] 1918-3003
  • [Journal-full-title] Journal of clinical medicine research
  • [ISO-abbreviation] J Clin Med Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3318853
  •  go-up   go-down


2. Kawataki T, Sato E, Sato T, Kinouchi H: Anaplastic ganglioglioma with malignant features in both neuronal and glial components--case report. Neurol Med Chir (Tokyo); 2010;50(3):228-31
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic ganglioglioma with malignant features in both neuronal and glial components--case report.
  • A 34-year-old man presented with a case of anaplastic ganglioglioma with malignant features in both neuronal and glial components manifesting as seizure episodes over 11 months.
  • The histological diagnosis was anaplastic ganglioglioma.
  • This rare case of anaplastic ganglioglioma with both neuronal and glial components, which were extremely positive for nestin, showed progressive worsening of the clinical course.
  • The expression of nestin may suggest that the origin or malignant transformation in anaplastic gangliogliomas is related to the undifferentiated neural stem cells.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology. Intermediate Filament Proteins / metabolism. Neoplasm Proteins / metabolism. Nerve Tissue Proteins / metabolism. Neuroglia / pathology. Neurons / pathology
  • [MeSH-minor] Adult. Anaplasia. Fatal Outcome. Humans. Male. Neoplasm Recurrence, Local. Nestin. Seizures / etiology. Seizures / pathology. Temporal Lobe / cytology. Temporal Lobe / metabolism. Temporal Lobe / pathology

  • Genetic Alliance. consumer health - Ganglioglioma.
  • Genetic Alliance. consumer health - Anaplastic Ganglioglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339274.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


3. Tanaka K, Sasayama T, Kawamura A, Kondoh T, Kanomata N, Kohmura E: Isolated oculomotor nerve paresis in anaplastic astrocytoma with exophytic invasion. Neurol Med Chir (Tokyo); 2006 Apr;46(4):198-201
Genetic Alliance. consumer health - Anaplastic Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated oculomotor nerve paresis in anaplastic astrocytoma with exophytic invasion.
  • A 30-year-old man presented with a supratentorial malignant glioma manifesting as isolated progressive left oculomotor nerve paresis.
  • The histological diagnosis was anaplastic astrocytoma.
  • Malignant glioma with exophytic growth in the temporal lobe should be considered in the differential diagnosis of isolated oculomotor nerve paresis.
  • [MeSH-minor] Adult. Astrocytes / pathology. Biomarkers, Tumor / analysis. Brain Stem / pathology. Cerebral Arteries / pathology. Cisterna Magna / pathology. Dominance, Cerebral / physiology. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness / pathology. Nerve Compression Syndromes / diagnosis. Nerve Compression Syndromes / etiology. Nerve Compression Syndromes / pathology. Nerve Compression Syndromes / surgery. Neuronavigation. Oculomotor Nerve / pathology. Oculomotor Nerve / surgery. Pons / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636512.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


Advertisement
4. Abiatari I, Esposito I, Oliveira TD, Felix K, Xin H, Penzel R, Giese T, Friess H, Kleeff J: Moesin-dependent cytoskeleton remodelling is associated with an anaplastic phenotype of pancreatic cancer. J Cell Mol Med; 2010 May;14(5):1166-79
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Moesin-dependent cytoskeleton remodelling is associated with an anaplastic phenotype of pancreatic cancer.
  • Cancer cells of different malignant lesions of human and transgenic mice pancreata were evaluated by immunohistochemistry.
  • Analysis of human and different transgenic mouse pancreatic cancers demonstrated that moesin is a phenotypic marker for anaplastic carcinoma, suggesting that this ERM protein plays a specific role in pancreatic carcinogenesis.
  • [MeSH-minor] Adult. Aged. Animals. Cadherins / metabolism. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / pathology. Cell Adhesion. Cell Line, Tumor. Cell Movement. Cell Proliferation. Extracellular Matrix / metabolism. Gene Expression Regulation, Neoplastic. Gene Silencing. Humans. Mice. Middle Aged. Neoplasm Invasiveness. Phenotype. Protein Transport. RNA, Small Interfering / metabolism. Young Adult. beta Catenin / metabolism

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432821.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / Microfilament Proteins; 0 / RNA, Small Interfering; 0 / beta Catenin; 144131-77-1 / moesin
  • [Other-IDs] NLM/ PMC3822753
  •  go-up   go-down


5. Dumas-Stoeckel S, Gambrelle J, Cornut PL, El Chehab H, Vighetto A, Denis P: [Central retinal vein and artery occlusions related to intraocular involvement of an anaplastic optochiasmatic glioma]. J Fr Ophtalmol; 2010 Oct;33(8):564-7
Genetic Alliance. consumer health - Glioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central retinal vein and artery occlusions related to intraocular involvement of an anaplastic optochiasmatic glioma].
  • Malignant optic tract gliomas are very aggressive and extremely rare tumors progressing to blindness and death in a few months.
  • We report here the case of a 73-year-old patient who presented a sudden decrease in visual acuity in his left eye associated with papilledema and headache: it revealed an optochiasmatic anaplastic glioma.
  • [MeSH-minor] Aged. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20692721.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Lagarrigue F, Dupuis-Coronas S, Ramel D, Delsol G, Tronchère H, Payrastre B, Gaits-Iacovoni F: Matrix metalloproteinase-9 is upregulated in nucleophosmin-anaplastic lymphoma kinase-positive anaplastic lymphomas and activated at the cell surface by the chaperone heat shock protein 90 to promote cell invasion. Cancer Res; 2010 Sep 1;70(17):6978-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase-9 is upregulated in nucleophosmin-anaplastic lymphoma kinase-positive anaplastic lymphomas and activated at the cell surface by the chaperone heat shock protein 90 to promote cell invasion.
  • Many anaplastic large cell lymphomas (ALCL) express the chimeric oncogene NPM-ALK, which drives malignant transformation and invasion.
  • [MeSH-major] HSP90 Heat-Shock Proteins / metabolism. Lymphoma, Large-Cell, Anaplastic / metabolism. Matrix Metalloproteinase 9 / biosynthesis. Protein-Tyrosine Kinases / biosynthesis
  • [MeSH-minor] Antigens, CD44 / metabolism. Cell Line, Tumor. Cell Membrane / metabolism. Dipeptides / pharmacology. Enzyme Activation. Enzyme Precursors / metabolism. Humans. Matrix Metalloproteinase Inhibitors. Neoplasm Invasiveness. Up-Regulation. rac1 GTP-Binding Protein / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20699364.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44 protein, human; 0 / Dipeptides; 0 / Enzyme Precursors; 0 / HSP90 Heat-Shock Proteins; 0 / Matrix Metalloproteinase Inhibitors; 0 / N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide; 0 / RAC1 protein, human; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 3.4.24.- / pro-matrix metalloproteinase 9; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.6.5.2 / rac1 GTP-Binding Protein
  •  go-up   go-down


7. Volavsek M, Lamovec J, Popović M: Extraneural metastases of anaplastic oligodendroglial tumors. Pathol Res Pract; 2009;205(7):502-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraneural metastases of anaplastic oligodendroglial tumors.
  • Extraneural metastases of malignant gliomas are rare.
  • According to the literature, they tend to appear in glioblastoma patients, but are exceptionally rare in anaplastic oligodendroglioma.
  • We report on an anaplastic oligodendroglioma and an anaplastic oligoastrocytoma that metastasized to cervical lymph nodes and bones.
  • In the second case, metastases to the sacrum and femur developed after surgery for a recurrent anaplastic oligoastrocytoma.
  • Our two cases reconfirm a rare but definite ability not only of glioblastoma but also of anaplastic oligodendroglioma, namely to metastasize to extraneural sites.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology. Femoral Neoplasms / secondary. Neoplasm Recurrence, Local. Oligodendroglia / pathology. Oligodendroglioma / secondary. Sacrum / pathology. Spinal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410385.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Lu X, Zhang C, Liu F, Sung CJ, Steinhoff MM, Lawrence WD: Primary peritoneal anaplastic giant cell carcinoma: case report of an unusual and highly malignant müllerian neoplasm. Arch Pathol Lab Med; 2008 Jan;132(1):109-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peritoneal anaplastic giant cell carcinoma: case report of an unusual and highly malignant müllerian neoplasm.
  • We report an unusual histologic type of PPC composed of anaplastic giant cells, which exhibited an aggressive clinical course.
  • However, this neoplasm was composed of diffuse anaplastic tumor giant cells, rather than serous carcinoma, which is the usual histologic type encountered in PPC.
  • We report this unusual histologic variant of PPC to raise awareness that anaplastic giant cell carcinoma may arise in the pelvic peritoneum as a primary tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18181661.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Gómez-Román JJ, Cobo ML, Val-Bernal JF: Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting as a bladder neoplasm. Pathol Int; 2008 Apr;58(4):249-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting as a bladder neoplasm.
  • Malignant lymphoma presenting in the bladder has been classified in primary cases, as the first sign of disseminated disease and as a secondary infiltration.
  • Reported herein is the case of a 45-year-old man with an anaplastic large cell lymphoma (anaplastic lymphoma kinase (ALK) and granzyme B positive) that presented as a bladder neoplasm.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Protein-Tyrosine Kinases / metabolism. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324919.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / Mucin-1; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


10. Kumar R, Singhal N, Jaiswal SK, Mahapatra AK: Recurrence in supratentorial anaplastic ependymoma. Pediatr Neurosurg; 2007;43(5):364-8
Genetic Alliance. consumer health - Anaplastic Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence in supratentorial anaplastic ependymoma.
  • AIM: To study the outcome and recurrence in supratentorial anaplastic ependymoma.
  • METHODS: Sixteen cases of supratentorial anaplastic ependymoma were reviewed.
  • Two operated and irradiated cases of differentiated ependymomas (grade II) developed anaplastic recurrence at follow-up of 5 years and 9 years, respectively, suggesting a malignant transformation of tumor at follow-up.
  • CONCLUSION: It is obvious that anaplastic ependymomas of the supratentorial compartment are aggressive tumors with high rates of recurrence even after gross total excision and irradiation.
  • Gross total excision and postoperative irradiation are not effective in preventing early recurrence in anaplastic ependymomas, and other factors affecting the outcome need to be analyzed.
  • [MeSH-major] Ependymoma / pathology. Neoplasm Recurrence, Local / pathology. Supratentorial Neoplasms / pathology

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17786000.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


11. Passone E, Pizzolitto S, D'Agostini S, Skrap M, Gardiman MP, Nocerino A, Scarzello G, Perilongo G: Non-anaplastic pleomorphic xanthoastrocytoma with neuroradiological evidences of leptomeningeal dissemination. Childs Nerv Syst; 2006 Jun;22(6):614-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-anaplastic pleomorphic xanthoastrocytoma with neuroradiological evidences of leptomeningeal dissemination.
  • CASE REPORT: A case of a non-anaplastic pleomorphic xanthoastrocytoma (PXA) presenting with leptomeningeal dissemination (LMD) affecting a 9-year-old girl is presented.
  • In a 5-year period, the tumour underwent malignant transformation, bringing the child to death because of the primary tumour progression.
  • CONCLUSION: To our knowledge, this is the first case of a non-anaplastic PXA presenting with disseminated disease.
  • Thus, it was thought important to describe this case in order to add further information regarding the spectrum of the presenting clinical features of this rare neoplasm and the phenomenon of LMD of non-malignant glioma.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Meningeal Neoplasms / complications. Neoplasm Recurrence, Local / etiology

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16369851.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen
  •  go-up   go-down


12. Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW: Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry; 2008 May;79(5):574-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.
  • METHODS: Between 1986 and 2004, 74 patients were diagnosed with high-grade meningioma: 33 with atypical and 41 with anaplastic meningioma.
  • RESULTS: Forty of 74 meningiomas were reclassified as atypical meningioma and 24 as anaplastic meningioma.
  • Overall and recurrence-free survivals were significantly longer in patients with atypical than in those with anaplastic meningioma: 142.5 versus 39.8 months and 138.5 versus 32.2 months, respectively (p<0.001).
  • In patients with anaplastic meningioma, the prognostic factors were brain invasion, adjuvant radiotherapy, malignant progression, p53 overexpression and extent of resection.
  • The p53 overexpression was the only factor associated with malignant progression (p = 0.009).
  • [MeSH-minor] Adult. Aged. Brain / pathology. Combined Modality Therapy. Cranial Irradiation. Disease Progression. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic / genetics. Humans. Ki-67 Antigen / genetics. Korea. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / classification. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome. Tumor Suppressor Protein p53 / genetics. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17766430.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


13. Williams MD, Hanna EY, El-Naggar AK: Anaplastic ameloblastic fibrosarcoma arising from recurrent ameloblastic fibroma: restricted molecular abnormalities of certain genes to the malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jul;104(1):72-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic ameloblastic fibrosarcoma arising from recurrent ameloblastic fibroma: restricted molecular abnormalities of certain genes to the malignant transformation.
  • A rare case of anaplastic ameloblastic fibrosarcoma (AS) arising in an ameloblastic fibroma (AF) of the maxilla of a 48-year-old patient 10 years after the primary excision is presented.
  • The recurrent tumor retained focal areas of AF but manifested heterogeneous malignant features ranging from low-grade spindle to highly pleomorphic sarcomas.
  • [MeSH-major] Fibrosarcoma / pathology. Maxillary Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology. Odontoma / pathology

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577546.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


14. Naydenov E, Tzekov C, Minkin K, Nachev S, Marinov M: [Malignant progression of an anaplastic ganglioglioma into a glioblastoma multiforme--report on two cases and review of the literature]. Khirurgiia (Sofiia); 2009;(2-3):69-74
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant progression of an anaplastic ganglioglioma into a glioblastoma multiforme--report on two cases and review of the literature].
  • We present two cases ofhistologically confirmed anaplastic ganglioglioma in which malignant progression into a glioblastoma multiforme was seen.
  • The tumor was excised partially and the histological result was anaplastic ganglioglioma (World Health Organization - WHO. gr. III).
  • The histological result was anaplastic ganglioglioma (WHO gr. ILL).
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology. Glioblastoma / pathology. Neoplasm Recurrence, Local / pathology


15. Leong MY, English M, McMullan D, Ramani P: Aberrant expression of beta-HCG in anaplastic large cell lymphoma. Pediatr Dev Pathol; 2008 May-Jun;11(3):230-4
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of beta-HCG in anaplastic large cell lymphoma.
  • We report a case of anaplastic large cell lymphoma (ALCL) showing aberrant expression of beta subunit of human chorionic gonadotrophin (beta-HCG).
  • Biopsy of the mass revealed a malignant neoplasm composed of large, pleomorphic cells with prominent nucleoli.
  • These malignant cells showed positive staining with CD30, ALK, epithelial membrane antigen, and beta-HCG.
  • [MeSH-major] Chorionic Gonadotropin, beta Subunit, Human / biosynthesis. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, Large-Cell, Anaplastic / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17990918.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


16. Ries S, Rnjak L, Mitrović Z, Kuvezdić KG, Nola M, Sucić M: CD13+ anaplastic large cell lymphoma with leukemic presentation and additional chromosomal abnormality. Diagn Cytopathol; 2010 Feb;38(2):141-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD13+ anaplastic large cell lymphoma with leukemic presentation and additional chromosomal abnormality.
  • Anaplastic large cell lymphoma (ALCL) is a highly malignant neoplasm characterized by pleomorphic appearance, different immunophenotypes and variable sites of involvement.
  • Expression of myeloid-associated markers in anaplastic large cell lymphomas may mislead the medical team and result in delay of diagnosis due to unusual phenotype.
  • [MeSH-major] Antigens, CD13 / biosynthesis. Chromosome Aberrations. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, Large-Cell, Anaplastic / physiopathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760763.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


17. Flatland B, Fry MM, Newman SJ, Moore PF, Smith JR, Thomas WB, Casimir RH: Large anaplastic spinal B-cell lymphoma in a cat. Vet Clin Pathol; 2008 Dec;37(4):389-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large anaplastic spinal B-cell lymphoma in a cat.
  • A left axillary mass was identified, and the results of fine needle aspiration cytology indicated malignant round cell neoplasia of possible histiocytic origin.
  • Euthanasia was performed due to the poor prognosis associated with severe, progressive neurologic signs and a malignant neoplasm.
  • The initial histologic diagnosis was anaplastic sarcoma, but immunohistochemical results indicated the cells were CD20+ and CD45R+ and CD3-, compatible with a diagnosis of B-cell lymphoma.
  • To the authors' knowledge, this is the first reported case of a feline spinal anaplastic B-cell lymphoma exhibiting bi- and multinucleated cells.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vet Clin Pathol. 2008 Dec;37(4):360-2 [19055569.001]
  • (PMID = 19055573.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Libertini S, Iacuzzo I, Ferraro A, Vitale M, Bifulco M, Fusco A, Portella G: Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Endocrinology; 2007 Nov;148(11):5186-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells.
  • Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors and shows morphological features of a highly malignant, undifferentiated neoplasm.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. LOVASTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690162.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / ONYX015; 0 / Viral Vaccines; 9LHU78OQFD / Lovastatin
  •  go-up   go-down


19. Schreuder T, Te Lintelo M, Kubat B, Koehler P: Anaplastic oligo-astrocytoma occurring after resection of a cerebral cavernous malformation; malignant transformation? Case report and review on etiology. J Neurol; 2010 Mar;257(3):349-53
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligo-astrocytoma occurring after resection of a cerebral cavernous malformation; malignant transformation? Case report and review on etiology.
  • Histological examination showed an anaplastic oligo-astrocytoma.
  • [MeSH-minor] Aged. Astrocytes / pathology. Brain / pathology. Brain / physiopathology. Brain / radiography. Cell Transformation, Neoplastic. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neovascularization, Pathologic / etiology. Neovascularization, Pathologic / pathology. Neovascularization, Pathologic / physiopathology. Neurosurgical Procedures / adverse effects. Oligodendroglia / pathology. Tomography, X-Ray Computed


20. Willenbrock K, Küppers R, Renné C, Brune V, Eckerle S, Weidmann E, Bräuninger A, Hansmann ML: Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. Haematologica; 2006 May;91(5):596-604
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: Anaplastic large cell lymphoma (ALCL) and classical Hodgkin's lymphoma (HL) are derived from different cell types, namely T cells and B cells, respectively.
  • RESULTS: HL samples clustered separately from ALCL samples, but HL and ALCL were found to be more closely related to each other than to any normal or malignant B-cell sample in the dataset.
  • [MeSH-major] Gene Expression Profiling. Hodgkin Disease / genetics. Lymphoma, Large-Cell, Anaplastic / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Transcription, Genetic
  • [MeSH-minor] Adult. B-Lymphocytes / metabolism. B-Lymphocytes / pathology. Cell Line, Tumor / metabolism. Cell Transformation, Neoplastic / genetics. Female. Gene Expression Regulation, Neoplastic. Humans. Leukemia / blood. Leukemia / genetics. Leukemia / metabolism. Leukemia / pathology. Lymphoma / classification. Lymphoma / genetics. Lymphoma / metabolism. Lymphoma / pathology. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Oligonucleotide Array Sequence Analysis. RNA, Complementary / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670065.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Complementary; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


21. Yi L, Zhou ZH, Ping YF, Chen JH, Yao XH, Feng H, Lu JY, Wang JM, Bian XW: Isolation and characterization of stem cell-like precursor cells from primary human anaplastic oligoastrocytoma. Mod Pathol; 2007 Oct;20(10):1061-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation and characterization of stem cell-like precursor cells from primary human anaplastic oligoastrocytoma.
  • A small population of stem cell-like precursors in solid tumors are linked to histological composition, progression, angiogenesis, metastasis, recurrence and drug resistance of a variety of malignant tumors.
  • Here, tumor stem cell-like precursors were identified from primary human anaplastic oligoastrocytomas by labeling of the tumor sections with nestin and CD133.
  • This study revealed for the first time that anaplastic human oligoastrocytomas contained stem cell-like precursors, which exhibit neural stem cell properties with tumorigenicity.
  • [MeSH-minor] Animals. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Brain / pathology. Fluorescent Antibody Technique, Indirect. Glycoproteins / analysis. Humans. Intermediate Filament Proteins / analysis. Magnetic Resonance Imaging. Mice. Mice, Nude. Neoplasm Transplantation. Nerve Tissue Proteins / analysis. Nestin. Peptides / analysis. Spheroids, Cellular / chemistry. Spheroids, Cellular / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660801.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Peptides
  •  go-up   go-down


22. Bruggers C, White K, Zhou H, Chen Z: Extracranial relapse of an anaplastic oligodendroglioma in an adolescent: case report and review of the literature. J Pediatr Hematol Oncol; 2007 May;29(5):319-22
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracranial relapse of an anaplastic oligodendroglioma in an adolescent: case report and review of the literature.
  • Oligodendroglioma is an uncommon childhood tumor and is more chemosensitive than other malignant glial neoplasms.
  • Treatment involves gross total resection, and if anaplastic, radiation and chemotherapy.
  • This chemotherapy may be promising in treating malignant oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Oligodendroglioma / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Fatal Outcome. Humans. Magnetic Resonance Imaging / methods. Male. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / therapy. Positron-Emission Tomography / methods. Recurrence

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483710.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Mosquera JM, Fletcher CD: Expanding the spectrum of malignant progression in solitary fibrous tumors: a study of 8 cases with a discrete anaplastic component--is this dedifferentiated SFT? Am J Surg Pathol; 2009 Sep;33(9):1314-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expanding the spectrum of malignant progression in solitary fibrous tumors: a study of 8 cases with a discrete anaplastic component--is this dedifferentiated SFT?
  • Among 948 cases of both intrathoracic and extrathoracic SFTs in our files accessioned between 1988 and 2008, we identified 8 cases of conventional SFT with a discrete anaplastic component, which we believe represents dedifferentiation.
  • [MeSH-minor] Adult. Aged. Anaplasia / genetics. Anaplasia / pathology. Antigens, CD34 / metabolism. Biomarkers, Tumor / metabolism. Chromosome Aberrations. Comparative Genomic Hybridization. DNA, Neoplasm / analysis. Female. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Sarcoma / genetics. Sarcoma / metabolism. Sarcoma / secondary. Tumor Suppressor Protein p53 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19718788.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


24. Asano K, Miyamoto S, Kubo O, Kikkukawa T, Yagihashi A, Ohkuma H: A case of anaplastic pleomorphic xanthoastrocytoma presenting with tumor bleeding and cerebrospinal fluid dissemination. Brain Tumor Pathol; 2006 Apr;23(1):55-63
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of anaplastic pleomorphic xanthoastrocytoma presenting with tumor bleeding and cerebrospinal fluid dissemination.
  • However, PXA cases having several recurrent patterns with poor prognosis have been reported in recent years, and a new concept of anaplastic PXA has been proposed.
  • From these findings, the histopathological diagnosis was anaplastic PXA.
  • Histopathological findings suggested anaplastic PXA from the first surgical specimens, and PXA recurred many times.
  • We thus believe that the patient displayed primary anaplastic PXA rather than secondary anaplastic PXA that results in malignant transformation.
  • [MeSH-minor] Biomarkers, Tumor. Fatal Outcome. Female. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Middle Aged. Mitosis / physiology. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095120.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


25. Chang HS, Nam KH, Chung WY, Park CS: Anaplastic thyroid carcinoma: a therapeutic dilemma. Yonsei Med J; 2005 Dec 31;46(6):759-64
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid carcinoma: a therapeutic dilemma.
  • Anaplastic thyroid carcinoma (ATC) is one of the most malignant human neoplasms and has a grave prognosis.
  • This study gives an update on our experience with this unusual neoplasm, with specific focus on the response to various treatment modalities.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2000 Sep;11(9):1083-9 [11061600.001]
  • [Cites] World J Surg. 1998 Jul;22(7):725-30 [9606289.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2335-42 [11413523.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jul 20;285(3):773-81 [11453659.001]
  • [Cites] Int Surg. 2001 Apr-Jun;86(2):117-21 [11918236.001]
  • [Cites] Curr Treat Options Oncol. 2000 Oct;1(4):353-7 [12057160.001]
  • [Cites] Curr Opin Oncol. 2003 Jan;15(1):78-83 [12490766.001]
  • [Cites] Semin Surg Oncol. 1999 Jan-Feb;16(1):64-9 [9890741.001]
  • [Cites] Am J Surg. 1999 Apr;177(4):337-9 [10326855.001]
  • [Cites] World J Surg. 2001 May;25(5):617-22 [11369989.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):395-402 [12656659.001]
  • [Cites] Hum Gene Ther. 2003 Dec 10;14(18):1741-51 [14670125.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1428-31 [2441842.001]
  • [Cites] Cancer. 1987 Nov 15;60(10):2372-5 [3664425.001]
  • [Cites] Cancer. 1990 Jul 15;66(2):321-30 [1695118.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):564-6 [1985750.001]
  • [Cites] Surgery. 1991 Dec;110(6):956-61; discussion 961-3 [1745983.001]
  • [Cites] Eur J Surg Oncol. 1992 Apr;18(2):83-8 [1582515.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1348-54 [8055459.001]
  • [Cites] Head Neck. 1995 Jan-Feb;17(1):41-7; discussion 47-8 [7883548.001]
  • [Cites] Head Neck. 1996 Jan-Feb;18(1):36-41 [8774920.001]
  • [Cites] Acta Cytol. 1996 Sep-Oct;40(5):953-8 [8842172.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):564-73 [9028369.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 May;118(5):728-31 [9591882.001]
  • [Cites] World J Surg. 1998 Jun;22(6):569-74 [9597930.001]
  • [Cites] Thyroid. 2001 Apr;11(4):315-25 [11349829.001]
  • (PMID = 16385650.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2810588
  •  go-up   go-down


26. Kościuch J, Zielonka TM, Ziółkowski B, Domagała-Kulawik J, Bogacka-Zatorska E, Chazan R: [Breast carcinoma and anaplastic gastric carcinoma with pleural metastases in patient after mastectomy 30 years ago]. Pneumonol Alergol Pol; 2006;74(1):129-31
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast carcinoma and anaplastic gastric carcinoma with pleural metastases in patient after mastectomy 30 years ago].
  • We describe a case of two simultaneous malignancies--anaplastic gastric carcinoma with pleural metastases and left breast carcinoma.
  • This observation confirms the important role of genetic factors in the pathogenesis of malignant diseases.
  • [MeSH-minor] Aged. Fatal Outcome. Female. Humans. Mastectomy, Radical. Neoplasm Recurrence, Local. Pedigree

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175993.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


27. Shi Y, Chen G, Zhou XG, Gong LP, Yu R, Zheng YY, Xie JL, Jin Y: [Clinicopathologic features of 66 cases of anaplastic lymphoma kinase positive and negative systemic anaplastic large cell lymphoma: a comparative study]. Zhonghua Bing Li Xue Za Zhi; 2010 Apr;39(4):235-9
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic features of 66 cases of anaplastic lymphoma kinase positive and negative systemic anaplastic large cell lymphoma: a comparative study].
  • OBJECTIVE: To study the clinicopathologic features of 66 cases of primary systemic anaplastic large cell lymphoma (ALCL), with emphasis on the differences between ALK-positive and ALK-negative cases.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, Large-Cell, Anaplastic / pathology. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antigens, CD30 / metabolism. Child. Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Gene Deletion. Humans. Male. Malignant Hyperthermia / etiology. Middle Aged. Mucin-1 / metabolism. Neoplasm Recurrence, Local. Receptor Protein-Tyrosine Kinases. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654121.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Mucin-1; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


28. Carda C, Ferrer J, Vilanova M, Peydró A, Llombart-Bosch A: Anaplastic carcinoma of the thyroid with rhabdomyosarcomatous differentiation: a report of two cases. Virchows Arch; 2005 Jan;446(1):46-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma of the thyroid with rhabdomyosarcomatous differentiation: a report of two cases.
  • Anaplastic carcinoma of the thyroid gland (ACT) is a highly malignant tumor that is almost invariably associated with a fatal outcome.
  • The spindle cell variant of ACT is usually indistinguishable from a true sarcoma and it can simulate fibrosarcoma, malignant fibrous histiocytoma (MFH), hemangiopericytoma and angiosarcoma or rhabdomyosarcoma.
  • These findings may contribute to the broadening of the differentiation spectrum of this unusual neoplasm.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15517365.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / MyoD Protein; 0 / MyoD1 myogenic differentiation protein; 0 / Myoglobin
  •  go-up   go-down


29. Lu Y, Zhao X, Wang E, Chen W, Huang Q: ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase". Leuk Res; 2010 Apr;34(4):475-82
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase".
  • CD30-positive anaplastic large cell lymphoma (ALCL) is a distinctive malignant large cell lymphoma of T-cell lineage, often presenting in lymph node or extranodal sites.
  • ALCL cases with extensive bone marrow and peripheral blood involvement manifested as "leukemic phase" are extremely rare and the most of those cases reported are anaplastic large cell lymphoma kinase (ALK) positive ALCL in childhood population.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Lymphoma, Large-Cell, Anaplastic / pathology. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19695703.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


30. Cheong JH, Kim CH, Kim JM, Oh YH: Transformation of intracranial anaplastic astrocytoma associated with neurofibromatosis type I into gliosarcoma: case report. Clin Neurol Neurosurg; 2010 Oct;112(8):701-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of intracranial anaplastic astrocytoma associated with neurofibromatosis type I into gliosarcoma: case report.
  • Gliosarcoma is an uncommon malignant brain tumor composed of distinct sarcomatous and malignant glial cell elements.
  • These tumors are defined as a variant of glioblastoma, and it can be developed by progression of the malignant glial cell tumors or primary tumors.
  • We report a rare case with gliosarcomatous recurrence of anaplastic astrocytoma with neurofibromatosis type 1 (NF-1) followed by chemoradiation therapy.
  • Histopathology of the tumor showed findings corresponding with anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Gliosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Neurofibromatosis 1 / pathology

  • Genetic Alliance. consumer health - Gliosarcoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20466481.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


31. Collin AC, Chekaroua K, Delaporte T, Droz JP, Peix JL, Delay E: [Anaplastic thyroid carcinoma: aggressive radical resection and cervical reconstruction. A case report]. Ann Chir; 2006 Dec;131(10):631-5
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaplastic thyroid carcinoma: aggressive radical resection and cervical reconstruction. A case report].
  • STUDY AIM: Anaplastic carcinoma of the thyroid is a rare but highly malignant tumor.
  • CONCLUSION: Anaplastic carcinoma is one of more aggressive neoplasm affecting humans.

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16824476.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


32. Wang CH, Shen YC, Hsieh JJ, Yeh KY, Chang JW: Clodronate alleviates cachexia and prolongs survival in nude mice xenografted with an anaplastic thyroid carcinoma cell line. J Endocrinol; 2006 Aug;190(2):415-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clodronate alleviates cachexia and prolongs survival in nude mice xenografted with an anaplastic thyroid carcinoma cell line.
  • Cancer cachexia is one of the most common manifestations of advanced malignant disease and is frequently associated with decreased survival.
  • Previously, we reported the establishment of a new anaplastic thyroid carcinoma cell line, Thena, and its mouse xenograft, Thena-Nu, which induced cachexia in athymic nude mice.
  • [MeSH-minor] Animals. Apoptosis. Cell Line, Tumor. Cell Proliferation / drug effects. Enzyme-Linked Immunosorbent Assay / methods. Granulocyte Colony-Stimulating Factor / analysis. Interleukin-6 / analysis. Leukemia Inhibitory Factor. Liver / pathology. Mice. Mice, Inbred BALB C. Mice, Nude. Necrosis. Neoplasm Transplantation. Transplantation, Heterologous. Tumor Necrosis Factor-alpha / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16899574.001).
  • [ISSN] 0022-0795
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Interleukin-6; 0 / Leukemia Inhibitory Factor; 0 / Lif protein, mouse; 0 / Tumor Necrosis Factor-alpha; 0813BZ6866 / Clodronic Acid; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


33. Sun XF, Zhen ZJ, Xiang XJ, Ling JY, Peng RJ, Xia Y, Zheng L, Luo WB, Lin H, Guan ZZ: [Efficacy of modified B-NHL-BFM-90 protocol on anaplastic T-cell lymphoma in children and adolescents]. Ai Zheng; 2009 May;28(5):506-10
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified B-NHL-BFM-90 protocol on anaplastic T-cell lymphoma in children and adolescents].
  • BACKGROUND AND OBJECTIVE: Anaplastic T-cell lymphoma in children and adolescents is an aggressive malignant non-Hodgkin's lymphoma (NHL).
  • This study was to evaluate the efficacy of modified B-NHL-BFM-90 protocol on anaplastic T-cell lymphoma in children and adolescents.
  • METHODS: From October 2002 to January 2008, 18 untreated anaplastic T-cell lymphoma patients aged less than 16 years were enrolled, and treated with modified B-NHL-BFM-90 protocol including cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, HD-methotrexate, vindesine, dexamethasone, cytarabine/HD-cytarabine.
  • CONCLUSIONS: Modified B-NHL-BFM-90 protocol, with tolerable toxicity, is an effective treatment regimen for anaplastic T-cell lymphoma in children and adolescents.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large-Cell, Anaplastic / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. L-Lactate Dehydrogenase / blood. Leukopenia / chemically induced. Male. Methotrexate / administration & dosage. Neoplasm Staging. Remission Induction. Stem Cell Transplantation. Thrombocytopenia / chemically induced. Vincristine / administration & dosage. Vindesine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624879.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; RSA8KO39WH / Vindesine; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


34. Guan X, Lai S, Lackey J, Shi J, Techavipoo U, Moulding HD, Flanders AE, Andrews DW: Revisiting anaplastic astrocytomas II: further characterization of an expansive growth pattern with visually enhanced diffusion tensor imaging. J Magn Reson Imaging; 2008 Dec;28(6):1322-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting anaplastic astrocytomas II: further characterization of an expansive growth pattern with visually enhanced diffusion tensor imaging.
  • PURPOSE: To seek to distinguish and visualize the different magnetic resonance imaging (MRI) growth patterns among malignant gliomas utilizing visually enhanced diffusion tensor imaging (DTI).
  • MATERIALS AND METHODS: Nineteen consecutive patients undergoing image-guided resection of a newly diagnosed malignant glioma underwent add-on acquisition of DTI data based on an Institutional Review Board (IRB)-approved imaging protocol during preoperative MRI scans for routine intraoperative image guidance.
  • CONCLUSION: We have successfully developed software that visually enhances the anatomic details of the tumor/fiber interface in patients with anaplastic astrocytomas.
  • [MeSH-minor] Adult. Aged. Female. Humans. Imaging, Three-Dimensional. Magnetic Resonance Imaging, Interventional. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19025901.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. O'Neill JP, O'Neill B, Condron C, Walsh M, Bouchier-Hayes D: Anaplastic (undifferentiated) thyroid cancer: improved insight and therapeutic strategy into a highly aggressive disease. J Laryngol Otol; 2005 Aug;119(8):585-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic (undifferentiated) thyroid cancer: improved insight and therapeutic strategy into a highly aggressive disease.
  • BACKGROUND: This review article discusses the clinical and diagnostic implications of anaplastic thyroid cancer, recognizing the aggressive nature of the disease and extensive disease progression upon diagnosis.
  • We question the pathological evolution of anaplasia as a 'de novo' disease or a post malignant transformation or dedifferentiation and the therapeutic implications of p53 mutation.
  • METHOD: An electronic search on Medline and Pubmed was performed under 'anaplastic thyroid carcinoma', 'anaplastic thyroid carcinogenesis', 'anaplastic thyroid carcinoma treatment reviews'.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Drug Resistance, Neoplasm. Humans. Neck Dissection. Neoadjuvant Therapy. Prognosis. Radiotherapy, Adjuvant. Thyroidectomy

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16102210.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 85
  •  go-up   go-down


36. Li S, Lee AK: Silicone implant and primary breast ALK1-negative anaplastic large cell lymphoma, fact or fiction? Int J Clin Exp Pathol; 2009;3(1):117-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silicone implant and primary breast ALK1-negative anaplastic large cell lymphoma, fact or fiction?
  • A series of anecdotal case reports and a recent epidemiological case-control study have suggested a possible association between silicone implant and the development of primary breast ALK1-negative anaplastic large cell lymphoma (ALCL), a rare type of peripheral T-cell lymphoma.
  • Molecular studies were needed to determine T-lineage differentiation of the malignant lymphoma cells.
  • [MeSH-major] Activin Receptors, Type II / metabolism. Breast Implants / adverse effects. Breast Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Diagnosis, Differential. Female. Humans. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Reconstructive Surgical Procedures

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Surg Pathol. 2008 Oct;16(4):407-13 [18480397.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1299-309 [18636016.001]
  • [Cites] Am J Hematol. 2009 Mar;84(3):133-9 [19199367.001]
  • [Cites] Plast Reconstr Surg. 2009 Mar;123(3):790-3 [19319041.001]
  • [Cites] Leuk Lymphoma. 2009 May;50(5):831-3 [19330656.001]
  • [Cites] Leuk Lymphoma. 2009 Jun;50(6):918-24 [19373599.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2009 Jul;17(4):301-6 [19318917.001]
  • [Cites] Clin Breast Cancer. 2009 Aug;9(3):145-54 [19661037.001]
  • [Cites] Ann Oncol. 2009 Dec;20(12):1993-9 [19570964.001]
  • [Cites] Ann Plast Surg. 2007 Jul;59(1):56-7 [17589261.001]
  • [Cites] Epidemiology. 2001 May;12(3):321-6 [11337605.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):115-9 [11908714.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e115-8 [12653596.001]
  • [Cites] Haematologica. 2004 Apr;89(4):ELT01 [15075114.001]
  • [Cites] J Am Acad Dermatol. 1995 Jun;32(6):939-42 [7751462.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):712-7 [7755157.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3124-8 [8874212.001]
  • [Cites] Plast Reconstr Surg. 1997 Aug;100(2):554-5 [9252643.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1341-9 [9308703.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 19;98(8):557-60 [16622125.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):561-4 [16983530.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):455-63 [18223553.001]
  • [Cites] Int J Hematol. 2008 Jun;87(5):491-7 [18414980.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2008 Jul;61(7):822-5 [17509956.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1265-8 [18594466.001]
  • [Cites] JAMA. 2008 Nov 5;300(17):2030-5 [18984890.001]
  • (PMID = 19918336.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  • [Other-IDs] NLM/ PMC2776268
  • [Keywords] NOTNLM ; ALCL / ALK1 / Breast implant / anaplastic large cell lymphoma / silicone
  •  go-up   go-down


37. Hillesheim PB, Farghaly H: Anaplastic spindle cell carcinoma, arising in a background of an ovarian mucinous cystic tumor: a case report with clinical follow up, review of the literature. Int J Clin Exp Pathol; 2010;3(8):808-11
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for spindle cell carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic spindle cell carcinoma, arising in a background of an ovarian mucinous cystic tumor: a case report with clinical follow up, review of the literature.
  • Anaplastic carcinoma (AC) of spindle cell type is an exceedingly rare ovarian malignant neoplasm.
  • To date, there have been less than ten cases of anaplastic spindle cell carcinoma reported in the medical literature.
  • Furthermore, our case is the first time this tumor has been described in a 40-year-old female with malignant spindle cells merging with conventional high grade adeno-carcinoma.
  • This report demonstrated that the findings of malignant spindle cell proliferation does not imply this entity to be carcinosarcoma.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):139-52 [11812936.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1467-76 [12409723.001]
  • [Cites] Cancer. 1979 Oct;44(4):1332-44 [498014.001]
  • [Cites] Am J Surg Pathol. 2008 Mar;32(3):383-9 [18300813.001]
  • [Cites] Am J Surg Pathol. 1991 Nov;15(11):1055-62 [1656803.001]
  • [Cites] J Pediatr Adolesc Gynecol. 2006 Feb;19(1):39-43 [16472728.001]
  • [Cites] Cancer. 1982 Jul 15;50(2):300-4 [7083135.001]
  • (PMID = 21151395.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2993232
  • [Keywords] NOTNLM ; Ovary / anaplastic carcinoma / case report / mucinous neoplasm / spindle cell
  •  go-up   go-down


38. Vujanić GM, Kelsey A, Perlman EJ, Sandstedt B, Beckwith JB: Anaplastic sarcoma of the kidney: a clinicopathologic study of 20 cases of a new entity with polyphenotypic features. Am J Surg Pathol; 2007 Oct;31(10):1459-68
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic sarcoma of the kidney: a clinicopathologic study of 20 cases of a new entity with polyphenotypic features.
  • We report 20 cases of a distinct, previously unrecognized renal neoplasm, anaplastic sarcoma of the kidney with polyphenotypic features.
  • The tumors were identified by re-reviewing tumors with unusual anaplastic features from the National Wilms Tumor Study Pathology Center, the International Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group trials.
  • Histologically, all tumors showed a spindle cell component which contained either multiple foci or diffuse, widespread anaplastic changes with bizarre pleomorphic cells and very atypical mitotic figures.
  • The nodules of cartilage showed both benign and malignant features, often within the same tumor.
  • They were usually diagnosed as anaplastic Wilms tumors and treated accordingly.
  • In the differential diagnosis, anaplastic Wilms tumor, primary renal synovial sarcoma, malignant mesenchymoma, ectomesenchymoma, and mesenchymal chondrosarcomas have been considered but none of these tumors shared the same features as the 20 cases described here which represent a distinct clinicopathologic entity with morphologic features of a polyphenotypic anaplastic sarcoma of the kidney.
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Child, Preschool. Desmin / analysis. Disease-Free Survival. Female. Gene Expression. Humans. Immunoenzyme Techniques. Infant. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Nephrectomy. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / metabolism. Phenotype. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Vimentin / analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895746.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / SYT-SSX fusion protein; 0 / Vimentin
  •  go-up   go-down


39. Schulz T, Proske S, Hartschuh W, Kurzen H, Paul E, Wünsch PH: High-grade trichoblastic carcinoma arising in trichoblastoma: a rare adnexal neoplasm often showing metastatic spread. Am J Dermatopathol; 2005 Feb;27(1):9-16
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade trichoblastic carcinoma arising in trichoblastoma: a rare adnexal neoplasm often showing metastatic spread.
  • It has been debated whether malignant transformation of trichoblastoma occurs.
  • The concept was recently forwarded that basal cell carcinoma is as a malignant neoplasm of follicular germinative cells and should be named trichoblastic carcinoma to show its relationship to trichoblastoma.
  • Almost all basal cell carcinomas are low-grade malignant neoplasms and develop metastases only very rarely, and if so, only after very long duration and untreated growth.
  • We add two further cases of trichoblastic carcinoma with anaplastic nuclei, arising in trichoblastoma.
  • Our cases emphasize that high-grade trichoblastic carcinoma develops via malignant transformation of trichoblastoma, and is very rare.
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Female. Humans. Immunoenzyme Techniques. Male. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15677970.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


40. Bellezza G, Cavaliere A, Del Sordo R, Sidoni A: Inflammatory myofibroblastic tumor of the larynx with anaplastic lymphoma kinase (ALK) protein overexpression. A case report. Tumori; 2006 Sep-Oct;92(5):449-51
Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the larynx with anaplastic lymphoma kinase (ALK) protein overexpression. A case report.
  • It may be easily misinterpreted as a malignant epithelial or mesenchymal spindle cell neoplasm.
  • Immunohistochemical investigation revealed that the neoplastic cells expressed anaplastic lymphoma kinase (ALK) protein.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168442.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


41. Recavarren RA, Yang J: Cytomorphologic features of primary anaplastic large cell lymphoma of the psoas muscle: a case report and literature review. Diagn Cytopathol; 2010 Mar;38(3):208-12
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphologic features of primary anaplastic large cell lymphoma of the psoas muscle: a case report and literature review.
  • Ki-1 (CD30) positive anaplastic large cell lymphoma (ALCL) is an uncommon malignancy, which may present with nodal as well as extra-nodal disease.
  • A cytodiagnosis of malignant cells favoring metastatic melanoma vs. poorly differentiated carcinoma was rendered.
  • Morphologic and immunohistochemical features later revealed a primary psoas muscle Ki-1 (CD30) positive ALCL with negative staining for anaplastic large cell lymphoma kinase (ALK).
  • Although rare, ALCL should be a diagnostic consideration when discohesive pleomorphic malignant cells are encountered on FNA of a muscle neoplasm.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Muscle Neoplasms / pathology. Psoas Muscles / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760764.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


42. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI: Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab; 2008 Jan;93(1):278-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
  • CONTEXT: Anaplastic thyroid carcinoma (ATC) can occur in the setting of differentiated thyroid carcinoma (DTC), which suggests a continuum in malignant progression from DTC to ATC.
  • PIK3CA kinase domain mutations were found in five (14%) ATCs, one of which had mutations in both differentiated and anaplastic areas.
  • [MeSH-minor] DNA, Neoplasm / genetics. Humans. Immunohistochemistry. PTEN Phosphohydrolase / genetics. PTEN Phosphohydrolase / metabolism. Polymerase Chain Reaction. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins B-raf / metabolism


43. Shi Y, Zou M, Collison K, Baitei EY, Al-Makhalafi Z, Farid NR, Al-Mohanna FA: Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. J Clin Endocrinol Metab; 2006 Jun;91(6):2373-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model.
  • CONTEXT: The characteristic feature of malignant neoplasm is invasion and metastasis.
  • OBJECTIVE: Our objective was to examine the effects of S100A4 expression knockdown by RNA interference on the growth and metastasis of human anaplastic thyroid carcinoma cells (ARO) and the sensibility of ARO to paclitaxel after S100A4 knockdown.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Proliferation. Disease Models, Animal. Female. Mice. Mice, Inbred BALB C. Neoplasm Invasiveness. Neoplasm Metastasis. Paclitaxel / pharmacology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551737.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins; 0 / S100a4 protein, mouse; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


44. Kalinova M, Krskova L, Brizova H, Kabickova E, Kepak T, Kodet R: Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status. Leuk Res; 2008 Jan;32(1):25-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status.
  • Anaplastic large cell lymphoma (ALCL) represents a heterogeneous group of malignant lymphoproliferative diseases with a consistent expression of the cytokine receptor CD30.
  • [MeSH-major] Antigens, CD30 / genetics. Lymphoma, Large-Cell, Anaplastic / genetics. Neoplasm, Residual / genetics. Protein-Tyrosine Kinases / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320171.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


45. Nobuhara Y, Onoda N, Yamashita Y, Yamasaki M, Ogisawa K, Takashima T, Ishikawa T, Hirakawa K: Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer; 2005 Mar 28;92(6):1110-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines.
  • Anaplastic thyroid cancer is one of the most aggressive human malignancies and the outcomes of conventional therapy have been far from satisfactory.
  • Recently, epidermal growth factor receptor (EGFR)-targeted therapy has been introduced as an alternative therapeutic strategy for highly malignant cancers.
  • This study was undertaken to investigate the expression of EGFR in anaplastic thyroid cancer cell lines, and to explore the potential of therapies targeting EGFR as a new therapeutic approach.
  • EGFR was universally expressed in anaplastic cancer cell lines at a variety of levels.
  • Specific EGFR stimulation with epidermal growth factor showed significant phosphorylation of ERK1/2 and Akt, and resulted in marked growth stimulation in an anaplastic thyroid cancer cell line, which highly expressed EGFR.
  • Inhibition of EGFR-transmitted growth stimulation by gefitinib was clearly observed in anaplastic thyroid cancer cell lines.
  • Our results suggested that EGFR-targeted therapy, such as gefitinib, might be worth further investigation for the treatment of anaplastic thyroid cancer.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Humans. Mice. Mice, Inbred BALB C. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Neoplasm Transplantation. Phosphorylation. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-akt. Transplantation, Heterologous


46. Isogai R, Fukao M, Kawada A: Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy. J Dermatol; 2007 Aug;34(8):556-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
  • Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is a malignant lymphoma with a relatively good prognosis, consisting of CD30-positive, undifferentiated, large cells.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large-Cell, Anaplastic / drug therapy. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17683387.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CHOP protocol; VNCOP-B protocol
  •  go-up   go-down


47. Mergan F, Jaubert F, Sauvat F, Hartmann O, Lortat-Jacob S, Révillon Y, Nihoul-Fékété C, Sarnacki S: Inflammatory myofibroblastic tumor in children: clinical review with anaplastic lymphoma kinase, Epstein-Barr virus, and human herpesvirus 8 detection analysis. J Pediatr Surg; 2005 Oct;40(10):1581-6
Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor in children: clinical review with anaplastic lymphoma kinase, Epstein-Barr virus, and human herpesvirus 8 detection analysis.
  • BACKGROUND/PURPOSE: Inflammatory myofibroblastic tumor (IMT) is considered as an intermediate neoplasm that may present malignant features.
  • Similar anaplastic lymphoma kinase (ALK) gene abnormalities as in anaplastic large cell lymphoma have been reported.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226988.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


48. Okuducu AF, Zils U, Michaelis SA, Michaelides S, von Deimling A: Ets-1 is up-regulated together with its target gene products matrix metalloproteinase-2 and matrix metalloproteinase-9 in atypical and anaplastic meningiomas. Histopathology; 2006 Jun;48(7):836-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ets-1 is up-regulated together with its target gene products matrix metalloproteinase-2 and matrix metalloproteinase-9 in atypical and anaplastic meningiomas.
  • The aim of this study was to determine the relationship between the expression of Ets-1, MMP-2 and -9 and the malignant potential of meningiomas.
  • Up-regulation of Ets-1, MMP-2 and MMP-9 expression was observed in atypical and anaplastic meningiomas.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16722933.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Protein c-ets-1; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


49. Preusser M, Haberler C, Hainfellner JA: Malignant glioma: neuropathology and neurobiology. Wien Med Wochenschr; 2006 Jun;156(11-12):332-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant glioma: neuropathology and neurobiology.
  • Malignant gliomas may manifest at any age including congenital and childhood cases.
  • Malignant gliomas comprise a spectrum of different tumor subtypes.
  • Within this spectrum, glioblastoma, anaplastic astrocytoma and anaplastic oligodendroglioma share as basic features preferential location in cerebral hemispheres, diffuse infiltration of brain tissue, fast tumor growth with fatal outcome within months or years.
  • Vascular proliferates and tissue necrosis are characteristic features of malignant gliomas, in particular glioblastoma.
  • In malignant glioma, distinct molecular pathways including the p53 pathway, the RB pathway and the EGFR pathway show frequent alterations that seem to be pathogenetically relevant.
  • Methylguanine-methyltransferase (MGMT) promoter methylation status in glioblastoma and 1p19q deletion status in anaplastic oligodendroglioma are associated with response to chemotherapy.
  • [MeSH-minor] Adult. Brain / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Child. Chromosome Aberrations. Female. Humans. Infant. Male. Neoplasm Invasiveness / pathology. Prognosis


50. Saqi A, Livolsi V, Mandel SJ, Baloch Z: Cervical chordoma masquerading as a thyroid neoplasm: a case report. Diagn Cytopathol; 2005 May;32(5):296-8
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical chordoma masquerading as a thyroid neoplasm: a case report.
  • We report a case of a paraspinal mass juxtaposed adjacent to the thyroid with intranuclear inclusions of papillary carcinoma, abundant eosinophilic cytoplasm of an oncocytic lesion, and pleomorphism of anaplastic carcinoma that expressed thyroglobulin and emulated a malignant thyroid neoplasm.
  • This case highlights the significance of including chordoma in the differential diagnosis of a thyroid neoplasm and interpreting thyroglobulin reactivity warily, because its inadvertent tracking during fine-needle aspirates (FNAs) can produce false positive staining of nonthyroidal cells.
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Intranuclear Inclusion Bodies / pathology. Neck. Neoplasm Invasiveness / pathology. Thyroglobulin / metabolism. Thyroidectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Chordoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15830368.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


51. Limentani SA, Asher A, Heafner M, Kim JW, Fraser R: A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J Neurooncol; 2005 May;72(3):241-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.
  • Two types of chemotherapy used in the treatment of patients with malignant glioma are carboplatin and Gliadel wafer [(3.85% 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU)].
  • The purpose of this study was to evaluate combination chemotherapy with Gliadel wafer and carboplatin in patients with high-grade, malignant glioma.
  • Fourteen (88%) patients had glioblastoma multiforme and 2 (12%) had anaplastic astrocytoma.
  • We conclude that administering systemic carboplatin is safe and well tolerated in the postoperative period immediately following resection and implantation of Gliadel wafer for the treatment of malignant glioma.
  • [MeSH-minor] Adult. Aged. Carmustine. Combined Modality Therapy. Disease Progression. Drug Implants. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures. Survival Analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937647.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Decanoic Acids; 0 / Drug Implants; 0 / Polyesters; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; BG3F62OND5 / Carboplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


52. Gelpi E, Popovic M, Preusser M, Budka H, Hainfellner J: Pleomorphic xanthoastrocytoma with anaplastic features presenting without GFAP immunoreactivity: implications for differential diagnosis. Neuropathology; 2005 Sep;25(3):241-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic xanthoastrocytoma with anaplastic features presenting without GFAP immunoreactivity: implications for differential diagnosis.
  • In these cases, the differential diagnosis needs to exclude other malignancies, for example, glioblastoma or malignant fibrous histiocytoma.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods. Melanoma / pathology. Microscopy, Confocal. Microscopy, Electron, Transmission. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16193842.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


53. Nakamura M, Tsuji O, Fujiyoshi K, Watanabe K, Tsuji T, Ishii K, Matsumoto M, Toyama Y, Chiba K: Cordotomy for patients with thoracic malignant astrocytoma. J Neurosurg Spine; 2010 Oct;13(4):418-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cordotomy for patients with thoracic malignant astrocytoma.
  • OBJECT: The optimal management of malignant astrocytomas remains controversial, and the prognosis of these lesions has been dismal regardless of the administered treatment.
  • In this study the authors investigated the surgical outcomes of cordotomy in patients with thoracic malignant astrocytomas to determine the effectiveness of this procedure.
  • METHODS: Cordotomy was performed in 5 patients with glioblastoma multiforme (GBM) and 2 with anaplastic astrocytoma (AA).
  • [MeSH-minor] Adolescent. Adult. Disease Progression. Encephalitis / etiology. Female. Glioblastoma / complications. Glioblastoma / pathology. Glioblastoma / surgery. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Pain, Postoperative. Paraplegia / etiology. Paraplegia / surgery. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20887138.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Mineva I, Gartner W, Hauser P, Kainz A, Löffler M, Wolf G, Oberbauer R, Weissel M, Wagner L: Differential expression of alphaB-crystallin and Hsp27-1 in anaplastic thyroid carcinomas because of tumor-specific alphaB-crystallin gene (CRYAB) silencing. Cell Stress Chaperones; 2005;10(3):171-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of alphaB-crystallin and Hsp27-1 in anaplastic thyroid carcinomas because of tumor-specific alphaB-crystallin gene (CRYAB) silencing.
  • In this study, we investigated the molecular mechanisms that affect the expression of alphaB-crystallin in benign goiters (n = 7) and highly malignant anaplastic thyroid carcinomas (ATCs) (n = 3).
  • In contrast, considerable expression of Hsp27-1 in benign and malignant thyroid tissue was demonstrated.
  • Immunofluorescence analysis revealed no relevant topological differences between benign and malignant thyrocytes in the cytoplasmic staining of both proteins.
  • [MeSH-minor] Animals. COS Cells. Cell Line, Tumor. Cloning, Molecular. DNA, Complementary / biosynthesis. Down-Regulation. Gene Silencing. Genes, Reporter. Goiter. HSP27 Heat-Shock Proteins. Heat-Shock Proteins / analysis. Heat-Shock Proteins / metabolism. Humans. Luciferases / genetics. Neoplasm Proteins / analysis. Neoplasm Proteins / metabolism. Oligonucleotide Array Sequence Analysis. Promoter Regions, Genetic. RNA, Messenger / metabolism. Tissue Extracts / chemistry. Tissue Extracts / genetics. Tissue Extracts / metabolism. Transfection. alpha-Crystallin B Chain

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antioxid Redox Signal. 2005 Mar-Apr;7(3-4):404-13 [15706087.001]
  • [Cites] J Physiol. 2005 May 1;564(Pt 3):715-22 [15718262.001]
  • [Cites] EMBO J. 1996 Jun 3;15(11):2695-706 [8654367.001]
  • [Cites] Eur J Biochem. 1996 Nov 15;242(1):56-66 [8954153.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2852-8 [10644752.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 1;29(1):152-5 [11125075.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):16059-63 [11274139.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3324-32 [11073954.001]
  • [Cites] Biochim Biophys Acta. 2001 Jul 30;1520(1):1-6 [11470154.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Aug 24;286(3):433-42 [11511077.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38731-6 [12140279.001]
  • [Cites] Exp Eye Res. 2003 Feb;76(2):145-53 [12565801.001]
  • [Cites] Circ Res. 2003 Feb 7;92(2):130-2 [12574138.001]
  • [Cites] Thyroid. 2003 Mar;13(3):283-90 [12729478.001]
  • [Cites] Cell Stress Chaperones. 2003 Spring;8(1):53-61 [12820654.001]
  • [Cites] Head Neck. 2003 Aug;25(8):662-70 [12884350.001]
  • [Cites] Surg Oncol. 2003 Aug;12(2):69-90 [12946479.001]
  • [Cites] Cell Cycle. 2003 Nov-Dec;2(6):579-84 [14512773.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] Endocr Relat Cancer. 2004 Jun;11(2):377-89 [15163312.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2543-8 [15197794.001]
  • [Cites] Nucleic Acids Res. 1986 May 27;14(10):4127-45 [3714473.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):9302-6 [2848260.001]
  • [Cites] Mol Cell Biol. 1989 Mar;9(3):1083-91 [2725488.001]
  • [Cites] J Histochem Cytochem. 1990 Jan;38(1):31-9 [2294148.001]
  • [Cites] Genomics. 1990 Aug;7(4):594-601 [2387586.001]
  • [Cites] Exp Eye Res. 1992 Mar;54(3):461-70 [1381680.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):639-45 [8425893.001]
  • [Cites] Eur J Biochem. 1994 Oct 1;225(1):1-19 [7925426.001]
  • [Cites] J Pathol. 1994 Nov;174(3):209-15 [7823254.001]
  • [Cites] Hum Genet. 1996 Mar;97(3):299-303 [8786068.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1643-54 [8635070.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 9;235(1):69-73 [9196037.001]
  • [Cites] J Cell Sci. 1997 Jul;110 ( Pt 13):1431-40 [9224761.001]
  • [Cites] Am J Physiol. 1998 May;274(5 Pt 2):H1457-64 [9612350.001]
  • [Cites] Genes Cells. 1998 Jul;3(7):443-57 [9753426.001]
  • [Cites] Am J Physiol. 1998 Dec;275(6 Pt 2):H2243-9 [9843825.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Apr;40(5):951-8 [10102292.001]
  • [Cites] Prog Retin Eye Res. 1999 Jul;18(4):463-509 [10217480.001]
  • [Cites] Reproduction. 2005 Jan;129(1):115-26 [15615903.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Mar;46(3):1092-8 [15728570.001]
  • [Cites] Proteomics. 2005 Feb;5(3):788-95 [15682460.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Mar;46(3):1085-91 [15728569.001]
  • (PMID = 16184762.001).
  • [ISSN] 1355-8145
  • [Journal-full-title] Cell stress & chaperones
  • [ISO-abbreviation] Cell Stress Chaperones
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRYAB protein, human; 0 / DNA, Complementary; 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Heat-Shock Proteins; 0 / Intermediate Filament Proteins; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / TFCP2L1 protein, human; 0 / Tissue Extracts; 0 / Transcription Factors; 0 / alpha-Crystallin B Chain; EC 1.13.12.- / Luciferases; EC 2.7.- / Protein Kinases
  • [Other-IDs] NLM/ PMC1226015
  •  go-up   go-down


55. Bollag R, Ramalingam P, Davis B, Reid-Nicholson M: Fine needle aspiration cytology of an endotracheal mass: report of a case with an unusual presentation of anaplastic large cell lymphoma. Acta Cytol; 2010 May-Jun;54(3):328-32
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of an endotracheal mass: report of a case with an unusual presentation of anaplastic large cell lymphoma.
  • BACKGROUND: Anaplastic large cell lymphoma (ALCL) is an uncommon hematolymphoid neoplasm characterized by malignant lymphocytes of T-cell phenotype.
  • In this location the diagnosis of ALCL can be especially difficult as its pleomorphic cytomorphology mimics that of a carcinoma, which is a more typical neoplasm arising in the trachea.
  • Fine needle aspiration biopsy of the endotracheal mass revealed discohesive malignant cells with abundant, pale cytoplasm and cerebriform, donut-shaped and horseshoe-shaped nuclei.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Tracheal Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518421.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


56. Shibui S: [Resent advances in chemotherapy for malignant brain tumors]. Gan To Kagaku Ryoho; 2005 Apr;32(4):442-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Resent advances in chemotherapy for malignant brain tumors].
  • Most malignant brain tumors are resistant to the chemotherapeutic agents because of the existence of several mechanisms or substances such as the blood-brain barrier, genes and proteins.
  • Loss of chromosome 1 p and 19 q is considered to be closely related to chemosensitivity in anaplastic oligodendrogliomas.
  • This is one of the breakthroughs in the field of chemotherapy for malignant brain tumors.
  • Multi-institutional randomized controlled study by JCOG Brain Tumor Study Group is the first trial for the treatment of malignant astrocytomas under well-established quality control and quality assurance systems.
  • It can be a model of clinical trials for malignant brain tumors in Japan.
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Clinical Trials, Phase II as Topic. Drug Resistance, Neoplasm. Humans. Nimustine / administration & dosage. Nitrosourea Compounds / pharmacology. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Procarbazine / administration & dosage. Quality Control. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15853207.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Nitrosourea Compounds; 0S726V972K / Nimustine; 35S93Y190K / Procarbazine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  • [Number-of-references] 27
  •  go-up   go-down


57. Kostron H, Rössler K: [Surgical intervention in patients with malignant glioma]. Wien Med Wochenschr; 2006 Jun;156(11-12):338-41
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical intervention in patients with malignant glioma].
  • 50 % of those are again malignant gliomas Grade III and Grade IV.
  • Despite all therapeutic approaches the median survival for glioblastomas is 15 months and for anaplastic gliomas Grade III 30 months.
  • New developments in the treatment of patients harboring malignant brain tumors allow an individual neurooncological treatment concept to be established to enhance overall survival and quality of life.
  • [MeSH-minor] Brain / pathology. Brain / surgery. Craniotomy / instrumentation. Humans. Image Processing, Computer-Assisted / instrumentation. Magnetic Resonance Imaging / instrumentation. Microsurgery / instrumentation. Neoplasm Invasiveness / pathology. Neuronavigation / instrumentation. Positron-Emission Tomography / instrumentation. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944364.001).
  • [ISSN] 0043-5341
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


58. Majores M, von Lehe M, Fassunke J, Schramm J, Becker AJ, Simon M: Tumor recurrence and malignant progression of gangliogliomas. Cancer; 2008 Dec 15;113(12):3355-63
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor recurrence and malignant progression of gangliogliomas.
  • BACKGROUND: Most gangliogliomas (GGs) are benign tumors, but tumor recurrence and malignant progression are observed in some patients.
  • METHODS: The authors analyzed their experience with 4 recurrent/progressive GGs (World Health Organization [WHO] grade I), 21 tumors with atypical features (WHO grade II), and 5 tumors with anaplastic histologic features (WHO grade III).
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease Progression. Epilepsy / epidemiology. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18988291.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Ko KW, Nam DH, Kong DS, Lee JI, Park K, Kim JH: Relationship between malignant subtypes of meningioma and clinical outcome. J Clin Neurosci; 2007 Aug;14(8):747-53
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between malignant subtypes of meningioma and clinical outcome.
  • We evaluated the relationship between histological malignant subtypes (WHO grade II or III) of meningioma and clinical outcome.
  • Of 485 patients treated surgically for intracranial meningioma at our hospital between 1994 and 2004, 49 (10%; 18 male, 31 female) had potentially malignant features.
  • The histological tumor subtypes within this group of patients included: atypical (n=23); clear cell (n=3); chordoid (n=5); rhabdoid (n=16); and anaplastic (n=4).
  • In view of the relatively high proportion of malignant subtypes (10%), we suggest that all meningiomas should be evaluated for malignancy.
  • [MeSH-minor] Female. Humans. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Neurosci. 2008 Jun;15(6):721-2; author reply 722-3 [18406141.001]
  • (PMID = 17499508.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


60. Kocher M, Kunze S, Eich HT, Semrau R, Müller RP: Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. Strahlenther Onkol; 2005 Mar;181(3):157-63
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
  • PURPOSE: To evaluate the feasibility, safety and efficacy of daily temozolomide concurrent with postoperative radiotherapy in malignant glioma.
  • PATIENTS AND METHODS: From 11/1999 to 03/2003, n = 81 patients aged 15-72 years (median 52 years, Karnofsky score 80-100% in 83%) suffering from primary glioblastoma (n = 47), anaplastic astrocytoma (n = 6), anaplastic oligodendroglioma (n = 16), and recurrent glioma (n = 12) were treated.
  • CONCLUSION: Postoperative radiochemotherapy with 30-33 daily doses of temozolomide (75 mg/m(2)) is safe in patients with malignant glioma.
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756519.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


61. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology; 2008 Mar 4;70(10):779-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
  • BACKGROUND: Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, may have activity in recurrent malignant gliomas.
  • METHODS: We retrospectively reviewed 55 consecutive patients with recurrent malignant gliomas who received bevacizumab and chemotherapy to determine efficacy, toxicity, and patterns of recurrence.
  • Six-month progression-free survival (PFS) was 42% for patients with glioblastoma and 32% for patients with anaplastic glioma.
  • CONCLUSIONS: Combination therapy with bevacizumab and chemotherapy is well-tolerated and active against recurrent malignant gliomas.
  • Bevacizumab may alter the recurrence pattern of malignant gliomas by suppressing enhancing tumor recurrence more effectively than it suppresses nonenhancing, infiltrative tumor growth.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Angiogenesis Inhibitors / administration & dosage. Angiogenesis Inhibitors / toxicity. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bevacizumab. Brain / drug effects. Brain / pathology. Brain / physiopathology. Clinical Trials as Topic / statistics & numerical data. Disease-Free Survival. Drug Resistance, Neoplasm / physiology. Drug Synergism. Female. Humans. Magnetic Resonance Imaging. Male. Meta-Analysis as Topic. Middle Aged. Retrospective Studies. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurology. 2009 Feb 24;72(8):773; author reply 773-4 [19248218.001]
  • [CommentIn] Neurology. 2009 Feb 24;72(8):772-3; author reply 773-4 [19237713.001]
  • (PMID = 18316689.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


62. Yoo H, Baia GS, Smith JS, McDermott MW, Bollen AW, Vandenberg SR, Lamborn KR, Lal A: Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas. Clin Cancer Res; 2007 Jan 1;13(1):68-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas.
  • Tumor hypoxia is often associated with more malignant phenotypes, resistance to therapy, and poor survival.
  • [MeSH-major] Anoxia. Antigens, Neoplasm / biosynthesis. Carbonic Anhydrases / biosynthesis. Meningioma / drug therapy. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17200340.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


63. Riemenschneider MJ, Hegi ME, Reifenberger G: MGMT promoter methylation in malignant gliomas. Target Oncol; 2010 Sep;5(3):161-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT promoter methylation in malignant gliomas.
  • Malignant gliomas often have the MGMT gene inactivated due to aberrant methylation of its promoter region.
  • In anaplastic gliomas, MGMT promoter methylation is a favorable prognostic marker independent of the type of therapy, i.e., radio- or chemotherapy.
  • [MeSH-minor] Animals. DNA, Neoplasm / genetics. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20725792.001).
  • [ISSN] 1776-260X
  • [Journal-full-title] Targeted oncology
  • [ISO-abbreviation] Target Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


64. Yang SH, Kim MK, Lee TK, Lee KS, Jeun SS, Park CK, Kang JK, Kim MC, Hong YK: Temozolomide chemotherapy in patients with recurrent malignant gliomas. J Korean Med Sci; 2006 Aug;21(4):739-44
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide chemotherapy in patients with recurrent malignant gliomas.
  • Numerous studies have demonstrated the clinical activity of temozolomide, a second-generation alkylating agent, against malignant brain tumors, however, its activity has not been reported in an Asian population.
  • This study analyzed the efficacy and toxicity of temozolomide in 25 adult patients with recurrent or progressive malignant gliomas after surgery and standard radiation therapy with or without chemotherapy, enrolled in our institution since July 2000.
  • Sixteen patients had glioblastoma multiforme (GBM), six with anaplastic astrocytoma, and three with anaplastic oligodendroglioma.
  • Temozolomide demonstrated moderate activity in recurrent and progressive malignant gliomas without serious toxicity.
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / therapeutic use. Brain / drug effects. Brain / pathology. Combined Modality Therapy. Drug Administration Schedule. Drug-Induced Liver Injury. Female. Humans. Leukopenia / chemically induced. Magnetic Resonance Imaging. Male. Middle Aged. Nausea / chemically induced. Neoplasm Recurrence, Local. Survival Analysis. Treatment Outcome. Vomiting / chemically induced

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Neurosci. 2001 Jul;8(4):325-7 [11437571.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):1036-8 [15758016.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1383-8 [11870183.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):552-60 [11905710.001]
  • [Cites] Cancer Treat Rev. 2002 Apr;28(2):115-20 [12297119.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):5846-52 [3664486.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):255-7 [11300334.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):259-66 [11300335.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Eur J Cancer. 1993;29A(7):940-2 [8499146.001]
  • [Cites] J Clin Epidemiol. 1997 Apr;50(4):441-50 [9179103.001]
  • [Cites] J Neurooncol. 1997 Sep;34(3):263-78 [9258818.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(6):484-8 [9332462.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):501-5 [11870527.001]
  • (PMID = 16891823.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Other-IDs] NLM/ PMC2729901
  •  go-up   go-down


65. Yokota T, Kouno J, Adachi K, Takahashi H, Teramoto A, Matsumoto K, Sugisaki Y, Onda M, Tsunoda T: Identification of histological markers for malignant glioma by genome-wide expression analysis: dynein, alpha-PIX and sorcin. Acta Neuropathol; 2006 Jan;111(1):29-38
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of histological markers for malignant glioma by genome-wide expression analysis: dynein, alpha-PIX and sorcin.
  • Glioblastoma multiforme (GBM), the most malignant class of glial neoplasm (grade IV in WHO criteria), carries the worst clinical prognosis among primary brain tumors in adults.
  • To establish criteria for this diagnostic approach, we scored glial tumor tissues of different histological grades according to the staining results; the scores were significantly higher in anaplastic astrocytomas and GBMs than in diffuse astrocytomas or normal brain tissues.
  • These findings indicated that levels of these three proteins might serve as histological markers for malignant glioma classification.
  • [MeSH-minor] DNA, Neoplasm / analysis. DNA, Neoplasm / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Rho Guanine Nucleotide Exchange Factors

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16320026.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ARHGEF6 protein, human; 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / Guanine Nucleotide Exchange Factors; 0 / Rho Guanine Nucleotide Exchange Factors; 0 / SRI protein, human; EC 3.6.4.2 / Dyneins
  •  go-up   go-down


66. Nakagawa Y, Kageji T, Mizobuchi Y, Kumada H, Nakagawa Y: Clinical results of BNCT for malignant brain tumors in children. Appl Radiat Isot; 2009 Jul;67(7-8 Suppl):S27-30
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical results of BNCT for malignant brain tumors in children.
  • It is very difficult to treat the patients with malignant brain tumor in children, especially under 3 years, because the conventional irradiation cannot be applied due to the damage of normal brain tissue.
  • We evaluated the clinical results and courses in patients with malignant glioma under 15 years.
  • There were 3 glioblastomas (GBM), 6 anaplastic astrocytomas(AAS), 7 primitive neuroectodermal tumors (PNET), 6 pontine gliomas and 1 anaplastic ependymoma.
  • Four of 6 anaplastic astrocytoma and 1 anaplastic ependymoma patients alive without tumor recurrence.
  • BNCT can be applied to malignant brain tumors in children, especially under 3 years instead of conventional radiation.
  • [MeSH-minor] Adolescent. Astrocytoma / pathology. Astrocytoma / radiotherapy. Child. Child, Preschool. Ependymoma / pathology. Ependymoma / radiotherapy. Fatal Outcome. Female. Glioblastoma / pathology. Glioblastoma / radiotherapy. Humans. Infant. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness / pathology. Neuroectodermal Tumors, Primitive / pathology. Neuroectodermal Tumors, Primitive / radiotherapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19406652.001).
  • [ISSN] 1872-9800
  • [Journal-full-title] Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
  • [ISO-abbreviation] Appl Radiat Isot
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


67. Milne AN, Sweeney KJ, O'Riordain DS, Pauwels P, Debiec-Rychter M, Offerhaus GJ, Jeffers M: Inflammatory myofibroblastic tumor with ALK/TPM3 fusion presenting as ileocolic intussusception: an unusual presentation of an unusual neoplasm. Hum Pathol; 2006 Jan;37(1):112-6
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor with ALK/TPM3 fusion presenting as ileocolic intussusception: an unusual presentation of an unusual neoplasm.
  • Inflammatory myofibroblastic tumor is a rare spindle cell lesion of indeterminate malignant potential occurring in both pulmonary and extrapulmonary tissues.

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360423.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


68. Chan DT, Poon WS, Chan YL, Ng HK: Temozolomide in the treatment of recurrent malignant glioma in Chinese patients. Hong Kong Med J; 2005 Dec;11(6):452-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
  • OBJECTIVE: To determine the anti-tumour efficacy and safety profile of temozolomide in local Chinese patients with recurrent malignant glioma.
  • Histology reviewed by a neuropathologist was required to show anaplastic glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, or mixed anaplastic oligoastrocytoma) or glioblastoma multiforme.
  • RESULTS: Twenty-two patients with recurrent malignant glioma were recruited between January 2001 and July 2004.
  • CONCLUSION. Preliminary results showed that temozolomide had an acceptable safety profile and anti-tumour activity in recurrent malignant glioma in local Chinese population.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16340021.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


69. Kobayashi H, Sawamura Y, Ishii N, Murata J, Iwasaki Y: [Temozolomide in the treatment of recurrent malignant glioma]. No Shinkei Geka; 2006 Dec;34(12):1241-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Temozolomide in the treatment of recurrent malignant glioma].
  • Temozolomide (TMZ) has demonstrated activity and acceptable toxicity for the treatment of recurrent malignant gliomas in carious prospective phase II studies.
  • No information is, however, available on TMZ treatment for recurrent malignant glioma in Japanese patients.
  • We report Hokkaido University Hospital experience on 35 adult patients with a recurrent malignant glioma, including 13 glioblastomas, 9 anaplastic astrocytomas, and 13 anaplastic oligondendroglial tumors.
  • These results suggested that the reported efficacy and toxicity profile of TMZ for the treatment of Japanese patients with recurrent malignant glioma is reproducible from the setting of clinical trials in the western countries.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17154070.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Clinical Trial, Phase II; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


70. Ellis JA, Waziri A, Balmaceda C, Canoll P, Bruce JN, Sisti MB: Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients. J Neurooncol; 2009 Dec;95(3):377-382
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients.
  • In general, surgical resection for pilocytic astrocytoma is thought to be curative with tumor recurrence or malignant transformation being relatively rare.
  • To evaluate the frequency of recurrence and malignant transformation of pilocytic astrocytoma in adults, we performed a retrospective analysis of all adult patients who underwent surgical resection for this tumor at our institution over a period of 10 years.
  • A high rate of malignant transformation was observed in the patients that underwent repeat surgery with 75% (3/4) progressing to anaplastic astrocytoma on pathological examination.
  • The potential for rapid tumor recurrence and malignant transformation necessitates careful post-operative follow-up for adult patients with this tumor.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19533024.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Yoshikawa K, Saito K, Kajiwara K, Nomura S, Ishihara H, Suzuki M: CyberKnife stereotactic radiotherapy for patients with malignant glioma. Minim Invasive Neurosurg; 2006 Apr;49(2):110-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CyberKnife stereotactic radiotherapy for patients with malignant glioma.
  • The authors report on their experience using the CyberKnife in 25 patients with malignant gliomas.
  • METHODS: Twenty-five patients with histologically proven malignant gliomas (18 glioblastoma: GB, 7 anaplastic astrocytoma: AA) were treated with the CyberKnife at Konan St. Hill Hospital between June 1998 and November 2002.
  • CONCLUSION: This is the first report of CyberKnife stereotactic radiotherapy applied to the treatment of malignant gliomas.
  • The frameless and painless CyberKnife stereotactic radiotherapy has the potential to be as useful for treatment of malignant glioma as other radiosurgical modalities.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / pathology. Radiosurgery / instrumentation. Robotics

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708341.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


72. Cossu A, Budroni M, Capobianco G, Pirino D, Palmieri G, Dessole S, Tanda F, Cesaraccio R, Cherchi PL: Epidemiology of malignant breast tumors in the province of Sassari (Sardinia, Italy) in the period 1992-2002. Eur J Gynaecol Oncol; 2005;26(5):505-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of malignant breast tumors in the province of Sassari (Sardinia, Italy) in the period 1992-2002.
  • The aim of this study was to evaluate the incidence of malignant breast tumors in the Province of Sassari, Sardinia (Italy) in the period 1992-2002 and to report the variations in comparison to the 1974-1985 period.
  • The analysis of our data showed that the overall number of malignant breast tumors was more than doubled from 1,139 cases in the period 1974-1985 to the 2,735 cases in the period 1992-2002, and the mean rate/100,000 changed from 43.4 to 106.0.
  • The analysis of the histotypes showed a relative reduction of ductal carcinoma in the period 1992-2002 in comparison to the previous period 1974-1985 (65.2% vs 82.0%) whereas the incidence of anaplastic forms increased in advanced ages of life.
  • [MeSH-minor] Adult. Age Distribution. Age Factors. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Ductal, Breast / etiology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / epidemiology. Carcinoma, Intraductal, Noninfiltrating / etiology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / epidemiology. Carcinoma, Lobular / etiology. Carcinoma, Lobular / pathology. Female. Humans. Incidence. Italy / epidemiology. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285566.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


73. Marton E, Feletti A, Orvieto E, Longatti P: Malignant progression in pleomorphic xanthoastrocytoma: personal experience and review of the literature. J Neurol Sci; 2007 Jan 31;252(2):144-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant progression in pleomorphic xanthoastrocytoma: personal experience and review of the literature.
  • It generally occurs in children and young adults and shows benign behaviour (WHO II), although an anaplastic variant and malignant potential have been described.
  • Pleomorphic xanthoastrocytomas with malignant transformation have been reported in three out of eight patients operated on for this type of tumor in our department in the last 15 years.
  • Histological examination revealed simple PXA in two patients and a PXA with anaplastic foci in the other.
  • Mean recurrence time was 5.7 years, with the original xanthoastrocytoma evolving to glioblastoma in two cases and anaplastic astrocytoma in the third.
  • A review of the available PXA literature dating back to 1979 revealed 16 cases of primary anaplastic astrocytoma and 21 cases of PXA with malignant transformation.
  • Our experience adds three more cases of malignant transformations, outlining once again the potential malignancy of pleomorphic xanthoastrocytomas and the fact that prognosis in these cases is the same as for primary anaplastic astrocytoma and glioblastoma.
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Child. Disease Progression. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local / pathology. Tomography, X-Ray Computed


74. Vajtai I, Kuhlen D, Kappeler A, Mariani L, Zimmermann A, Paulus W: Rapid spontaneous malignant progression of supratentorial tanycytic ependymoma with sarcomatous features - "Ependymosarcoma". Pathol Res Pract; 2010 Jul 15;206(7):493-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid spontaneous malignant progression of supratentorial tanycytic ependymoma with sarcomatous features - "Ependymosarcoma".
  • By analogy to gliosarcoma, the term "ependymosarcoma" has recently been coined to thematize the rare phenomenon of a malignant mesenchymal component arising within an ependymoma.
  • Histology showed a biphasic glial-sarcomatous architecture with remnants of the original ependymoma now displaying hypercellularity and atypical - yet not frankly anaplastic - features.
  • To the best of our knowledge, this is the first documentation of tanycytic ependymoma undergoing malignant transformation, one driven by a highly anaplastic mesenchymal component, corresponding to "ependymosarcoma".
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Ependymoma / pathology. Gliosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Supratentorial Neoplasms / pathology

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19853384.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


75. Bozinov O, Kalk JM, Krayenbühl N, Woernle CM, Sure U, Bertalanffy H: Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas. Neurol Med Chir (Tokyo); 2010;50(8):617-21
Hazardous Substances Data Bank. TENIPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas.
  • This gene is highly expressed in various types of human tumors including malignant gliomas.
  • The expression level of IL-13Ralpha2 was examined in a total of 45 tissue samples of anaplastic astrocytomas (AAs) World Health Organization (WHO) grade III, glioblastomas (GBMs) WHO grade IV, and first-recurrent glioblastomas (frGBMs) after treatment with radiation and chemotherapy.
  • The expression level of IL-13Ralpha2 (15 fold) was significantly reduced in frGBMs compared to the primary GBMs (p = 0.014), and significantly reduced by more than 15 fold (p = 0.003) in all untreated malignant astrocytomas (AAs and GBMs) compared with treated frGBMs.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Interleukin-13 Receptor alpha2 Subunit / metabolism. Neoplasm Recurrence, Local / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20805641.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Actins; 0 / Exotoxins; 0 / IL13-PE38QQR; 0 / Immunotoxins; 0 / Interleukin-13; 0 / Interleukin-13 Receptor alpha2 Subunit; 0S726V972K / Nimustine; 63231-63-0 / RNA; 957E6438QA / Teniposide
  •  go-up   go-down


76. Alexiou GA, Moschovi M, Stefanaki K, Prodromou C, Sfakianos G, Prodromou N: Malignant progression of a pleomorphic xanthoastrocytoma in a child. Neuropediatrics; 2010 Aug;41(2):69-71
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant progression of a pleomorphic xanthoastrocytoma in a child.
  • Pleomorphic xanthoastrocytoma (PXA) is a recently recognized rare cerebral neoplasm that predominantly affects young patients.
  • The lesion was excised and histology disclosed the presence of a PXA with anaplastic features.
  • Histology revealed that the presence of a malignant PXA with anaplastic features.

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart.New York.
  • (PMID = 20799153.001).
  • [ISSN] 1439-1899
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


77. Kurimoto M, Nagai S, Hamada H, Tsuboi Y, Hayashi N, Kubota T, Endo S: Malignant transformation of supratentorial clear cell ependymoma. Neuropathology; 2009 Jun;29(3):299-302
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of supratentorial clear cell ependymoma.
  • Recurrence of clear cell ependymoma is not a rare condition, but malignant transformation of clear cell ependymoma has not yet been well presented.
  • Thereafter, the recurrent tumors showed anaplastic features such as nuclear pleomorphisms and necrosis with pseudopallisading.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647267.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


78. Momota H, Narita Y, Matsushita Y, Miyakita Y, Shibui S: p53 abnormality and tumor invasion in patients with malignant astrocytoma. Brain Tumor Pathol; 2010 Oct;27(2):95-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 abnormality and tumor invasion in patients with malignant astrocytoma.
  • Malignant astrocytomas are characterized by diffusely infiltrating nature, and the abnormality of p53 is a cytogenetic hallmark of astrocytic tumors.
  • To elucidate the relationship between p53 abnormality and invasiveness of the tumors, we studied mutation and protein expression of p53 in 48 consecutive patients with malignant astrocytoma (14 anaplastic astrocytomas and 34 glioblastoma multiformes).
  • As diffuse and multiple features on imaging modalities represent invasive characteristics of the tumors, p53 abnormalities may affect the invasive and aggressive nature of malignant astrocytomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. DNA, Neoplasm / genetics. Female. Glial Fibrillary Acidic Protein / genetics. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Mitotic Index. Mutation / genetics. Mutation / physiology. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Survival Analysis. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Vascular Endothelial Growth Factor A / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046311.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Glial Fibrillary Acidic Protein; 0 / Tumor Suppressor Protein p53; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


79. Ngo TT, Peng T, Liang XJ, Akeju O, Pastorino S, Zhang W, Kotliarov Y, Zenklusen JC, Fine HA, Maric D, Wen PY, De Girolami U, Black PM, Wu WW, Shen RF, Jeffries NO, Kang DW, Park JK: The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst; 2007 Apr 18;99(8):639-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas.
  • BACKGROUND: Malignant gliomas are generally resistant to all conventional therapies.
  • Notable exceptions are anaplastic oligodendrogliomas with loss of heterozygosity on chromosome 1p (1p+/-).
  • Patients with 1p+/- anaplastic oligodendroglioma frequently respond to procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, and vincristine.
  • Because the underlying biologic basis for this clinical finding is unclear, we evaluated differentially expressed 1p-encoded proteins in 1p+/- and 1p+/+ malignant glioma cell lines and then examined whether their expression was associated with outcome of patients with anaplastic oligodendroglioma.
  • METHODS: We used a comparative proteomic screen of A172 (1p+/-) and U251 (1p+/+) malignant glioma cell lines to identify differentially expressed 1p-encoded proteins, including stathmin, a microtubule-associated protein.
  • 1p+/- and 1p+/+ anaplastic oligodendroglioma specimens from 24 patients were assessed for stathmin expression by immunohistochemistry.
  • RNA inhibition and cDNA transfection experiments tested effects of stathmin under- and overexpression, respectively, on the in vitro and in vivo resistance of malignant glioma cells to treatment with nitrosourea.
  • Nitrosoureas induced mitotic arrest in malignant glioma cells, and this effect was greater in cells with decreased stathmin expression.
  • CONCLUSIONS: Loss of heterozygosity for the stathmin gene may be associated with improved outcomes of patients with 1p+/- anaplastic oligodendroglioma tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Drug Resistance, Neoplasm. Glioma / genetics. Nitrosourea Compounds / therapeutic use. Oligodendroglioma / genetics. Stathmin / genetics
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Base Sequence. Cell Line, Tumor. Chromosome Mapping. DNA Primers. DNA, Neoplasm / genetics. Electrophoresis, Gel, Two-Dimensional. Humans. In Situ Hybridization, Fluorescence. Molecular Sequence Data. RNA, Neoplasm / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440165.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Nitrosourea Compounds; 0 / RNA, Neoplasm; 0 / Stathmin
  •  go-up   go-down


80. Baia GS, Dinca EB, Ozawa T, Kimura ET, McDermott MW, James CD, VandenBerg SR, Lal A: An orthotopic skull base model of malignant meningioma. Brain Pathol; 2008 Apr;18(2):172-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An orthotopic skull base model of malignant meningioma.
  • These tumors had histopathologic characteristics of anaplastic meningiomas including high cellularity, nuclear pleomorphism, cellular pattern loss, necrosis and conspicuous mitosis.
  • The pattern of hypoxia was also similar to human malignant meningiomas.
  • Thus, we describe a malignant meningioma model system that will be useful for investigating the biology of meningiomas and for preclinical assessment of therapeutic agents.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Transplantation / methods. Skull Base Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18093250.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / 1R03NS054829-01; United States / NCI NIH HHS / CA / P50CA097257
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Tumor Suppressor Proteins; 147336-22-9 / Green Fluorescent Proteins; 298-93-1 / thiazolyl blue; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


81. Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E: MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer; 2009 Sep 15;125(6):1407-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC.
  • Here, we performed real-time reverse transcriptase polymerase chain reaction (RT-PCR) assays on 43 glioma samples (17 glioblastoma, 6 anaplastic astrocytoma, 10 low-grade astrocytoma, 6 oligodendroglioma and 4 ependymoma) and 6 glioma cell lines.
  • Finally, multifocal lesions on enhanced MRI of 7 malignant gliomas were associated with higher expression levels of miR-10b (p = 0.02).
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Up-Regulation

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC
  • (PMID = 19536818.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / LILRB2 protein, human; 0 / Membrane Glycoproteins; 0 / RHOC protein, human; 0 / RNA, Messenger; 0 / Receptors, Immunologic; 0 / Receptors, Urokinase Plasminogen Activator; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


82. Makni SK, Bahri I, Ellouze S, Mnif H, Ayadi L, Ghariani M, Khmiri H, Boudawara T: [Malignant struma ovarii: a case report]. J Gynecol Obstet Biol Reprod (Paris); 2005 Dec;34(8):815-8
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant struma ovarii: a case report].
  • Malignant transformation of struma ovarii is exceptional (less than 1%).
  • Immunohistochemistry is highly contributive in the anaplastic forms.
  • We report a case of malignant struma ovarii with metastasis observed in a 65-year-old woman who died rapidly from her disease.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Fatal Outcome. Female. Humans. Immunohistochemistry. Keratin-7. Keratins / analysis. Neoplasm Metastasis. Radiotherapy. Thyroglobulin / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16319775.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / KRT7 protein, human; 0 / Keratin-7; 68238-35-7 / Keratins; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


83. Liu Y, Liu M, Li F, Wu C, Zhu S: Malignant meningiomas: a retrospective study of 22 cases. Bull Cancer; 2007 Oct;94(10):E27-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant meningiomas: a retrospective study of 22 cases.
  • Malignant (anaplastic) meningioma constitutes a rare subset of meningioma.
  • The aim of the study was to study clinical features and management of malignant meningiomas.
  • Twenty-two patients with malignant meningiomas were surgically treated in our department between January 1986 and January 2005 in Qilu hospital, and we reviewed each patient's clinical records, radiological findings, operative reports, and pathological examinations.
  • Surgical resection and adjuvant radiotherapy are the main treatments for malignant meningiomas, and the degree of tumor removal is the leading factor determining postoperative recurrence and survival.
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964977.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


84. Brecknell JE, McLean CA, Hirano H, Malham GM: Disseminated intravascular coagulation complicating resection of a malignant meningioma. Br J Neurosurg; 2006 Aug;20(4):239-41
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated intravascular coagulation complicating resection of a malignant meningioma.
  • A 70-year-old woman developed disseminated intravascular coagulation (DIC) during a craniotomy for a parasagittal anaplastic/malignant meningioma.
  • The tumour was demonstrated to express tissue factor, an important causative factor in other tumour associated DIC and previously shown to be expressed by malignant meningiomas.
  • [MeSH-major] Brain Neoplasms / surgery. Disseminated Intravascular Coagulation / etiology. Intraoperative Complications / etiology. Meningioma / surgery. Neoplasm Proteins / metabolism. Thromboplastin / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954076.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 9035-58-9 / Thromboplastin
  •  go-up   go-down


85. Vordermark D, Kölbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M: Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer; 2005;5:55
Hazardous Substances Data Bank. TENIPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma.
  • BACKGROUND: Hypofractionated stereotactic radiotherapy (HFSRT) is one salvage treatment option in previously irradiated patients with recurrent malignant glioma.
  • METHODS: Between 1997 and 2003, 19 patients with recurrent malignant glioma (14 glioblastoma on most recent histology, 5 anaplastic astrocytoma) were treated with HFSRT.
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Disease Progression. Dose-Response Relationship, Radiation. Glioblastoma / pathology. Glioblastoma / surgery. Humans. Neoplasm Recurrence, Local. Nimustine / pharmacology. Prognosis. Recurrence. Stereotaxic Techniques. Teniposide / pharmacology. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2000 Apr;23(2):155-9 [10776976.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):397-409 [11139371.001]
  • [Cites] Am J Clin Oncol. 2002 Dec;25(6):606-11 [12478010.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3276-84 [12947063.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2678-86 [14669289.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Bull Cancer. 2004 Nov;91(11):883-9 [15582893.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41 [10613305.001]
  • [Cites] Radiother Oncol. 1999 Oct;53(1):53-7 [10624854.001]
  • [Cites] Am J Clin Oncol. 1997 Jun;20(3):226-9 [9167741.001]
  • [Cites] Radiother Oncol. 1997 Oct;45(1):83-8 [9364636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):293-8 [10030252.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):393-8 [9069312.001]
  • (PMID = 15924621.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0S726V972K / Nimustine; 957E6438QA / Teniposide
  • [Other-IDs] NLM/ PMC1156875
  •  go-up   go-down


86. Pruyt M, Devriendt D, Vanneste A: Malignant melanoma and adenocarcinoma of a Barrett oesophagus. Acta Chir Belg; 2006 Sep-Oct;106(5):616-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma and adenocarcinoma of a Barrett oesophagus.
  • An adenocarcinoma with a malignant melanoma in a Barrett oesophagus is extremely rare.
  • The diagnosis of a malignant melanoma can be difficult but can be made by tissue examination with a special immunoreaction with several markers to see it expresses S-100, but lacks activity for KER and EMA.
  • S-100 is relatively non-specific as a single immunodeterminant in the diagnostic separation of melanoma and anaplastic carcinoma, but very sensitive.
  • [MeSH-minor] Antigens, Neoplasm. Humans. Immunohistochemistry. Male. Melanoma-Specific Antigens. Middle Aged. Neoplasm Proteins / analysis. Phosphopyruvate Hydratase / analysis. S100 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168284.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


87. Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE 2nd, Dowell JM, Friedman AH, Friedman HS: Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer; 2005 Jan 15;103(2):329-38
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
  • BACKGROUND: In the current study, the authors report a Phase II trial of irinotecan (CPT-11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX-2 inhibitor, among MG patients with recurrent disease.
  • RESULTS: Thirty-four of the 37 patients enrolled in the current study (92%) were diagnosed with recurrent GBM and 3 patients (8%) were diagnosed with recurrent anaplastic astrocytoma (AA).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Pyrazoles / administration & dosage. Sulfonamides / administration & dosage
  • [MeSH-minor] Adult. Aged. Biological Availability. Celecoxib. Confidence Intervals. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Magnetic Resonance Imaging. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Probability. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15558802.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P20 CA096890; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / M01 RR 30; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; 7673326042 / irinotecan; JCX84Q7J1L / Celecoxib; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


88. Pavelić K, Dedivitis RA, Kapitanović S, Cacev T, Guirado CR, Danić D, Radosević S, Brkić K, Pegan B, Krizanac S, Kusić Z, Spaventi S, Bura M: Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions. Mutat Res; 2006 Jul 25;599(1-2):45-57
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
  • We undertook this study to analyze FHIT and p53 gene status in different benignant and malignant thyroid tumors.
  • The majority of the malignant thyroid cancers displayed aberrant expression of FHIT gene, concominant with p53 gene inactivation.
  • We found higher incidence of p53 mutation and aberrant processing of FHIT mRNA in malignant tumors (papillary, follicular, medullary and anaplastic carcinomas) and in those tumors with distant metastasis.
  • Concomitant aberration of FHIT gene and p53 could be responsible for development of highly malignant types of thyroid cancer and may be considered as a prognostic marker for these tumors.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Genes, p53. Mutation. Neoplasm Proteins / genetics. Thyroid Diseases / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Apoptosis. Female. Flow Cytometry. Gene Expression. Humans. Immunohistochemistry. Loss of Heterozygosity. Male. Mice. Mice, Nude. Middle Aged. Molecular Biology. Neoplasm Transplantation. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698048.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


89. Tsuboi Y, Kurimoto M, Nagai S, Kamiyama H, Endo S: Malignant transformation of oligoastrocytoma: a case report. Brain Tumor Pathol; 2007;24(2):63-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of oligoastrocytoma: a case report.
  • We report a case of oligoastrocytoma resembling dysembryoplastic neuroepithelial tumor (DNT) with malignant transformation.
  • The pathological diagnosis was anaplastic oligoastrocytoma with a MIB-1 staining index of 79%.
  • The authors concluded that this tumor could be a malignant transformation of oligoastrocytoma mimicking DNT, and we wish to give warning that the presence of a glioneuronal component is not an absolute benign hallmark.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology. Neuroectodermal Tumors, Primitive / pathology

  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095133.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


90. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE: Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys; 2009 Sep 1;75(1):156-63
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
  • The objectives of this study were to determine the safety and activity of this combination in malignant gliomas.
  • METHODS AND MATERIALS: After prior treatment with standard radiation therapy patients with recurrent glioblastoma (GBM) and anaplastic gliomas (AG) received bevacizumab (10 mg/kg intravenous) every 2 weeks of 28-day cycles until tumor progression.
  • Radiographic responses, duration of disease control, and survival suggest that this regimen is active in recurrent malignant glioma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Astrocytoma. Brain Neoplasms. Neoplasm Recurrence, Local. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2004 Dec;27(6):646-8 [15577450.001]
  • [Cites] BMC Cancer. 2005;5:55 [15924621.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8136-9 [16258121.001]
  • [Cites] Neurosignals. 2005;14(5):207-21 [16301836.001]
  • [Cites] Lung Cancer. 2006 Jan;51(1):97-103 [16213059.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):769-77 [16391297.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):626-35 [16837971.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Acta Oncol. 2006;45(7):848-55 [16982549.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):397-409 [11139371.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):39-44 [11196192.001]
  • [Cites] J Magn Reson Imaging. 2002 Mar;15(3):233-40 [11891967.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1399-405 [12684411.001]
  • [Cites] Science. 2003 May 16;300(5622):1155-9 [12750523.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1017-21 [15001240.001]
  • [Cites] Cancer Cell. 2004 May;5(5):429-41 [15144951.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31 [231022.001]
  • [Cites] Neurology. 1980 Sep;30(9):907-11 [6252514.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Sep;6(9):1215-28 [7007303.001]
  • [Cites] Science. 1983 Feb 25;219(4587):983-5 [6823562.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):723-7 [3940638.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Radiother Oncol. 2007 Feb;82(2):185-90 [17257702.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):472-8 [17498568.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5076-82 [17545583.001]
  • [Cites] Trends Mol Med. 2007 Jun;13(6):223-30 [17462954.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):271-8 [18182667.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):193-205 [18328424.001]
  • [Cites] N Engl J Med. 2008 May 8;358(19):2039-49 [18463380.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):484-90 [18234445.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):324-5 [18474308.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1372-80 [18355978.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):870-8 [17293237.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Magn Reson Med. 1992 Mar;24(1):174-6 [1556924.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):375-83 [9069310.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]
  • (PMID = 19167838.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00595322
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ NIHMS460357; NLM/ PMC3659401
  •  go-up   go-down


91. Stojic J, Hagemann C, Haas S, Herbold C, Kühnel S, Gerngras S, Roggendorf W, Roosen K, Vince GH: Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci Res; 2008 Jan;60(1):40-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas.
  • Glioblastomas (GBM) are the most prevalent type of malignant primary brain tumor in adults.
  • They may manifest de novo or develop from low-grade astrocytomas (LGA) or anaplastic astrocytomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Disease Progression. Female. Gene Expression Regulation, Enzymologic / genetics. Gene Expression Regulation, Neoplastic / genetics. Humans. Male. Matrix Metalloproteinase 9 / genetics. Middle Aged. Neoplasm Invasiveness / genetics. Predictive Value of Tests. Prognosis. RNA, Messenger / analysis. RNA, Messenger / metabolism. World Health Organization

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980449.001).
  • [ISSN] 0168-0102
  • [Journal-full-title] Neuroscience research
  • [ISO-abbreviation] Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 3.4.24.- / Matrix Metalloproteinase 11; EC 3.4.24.- / Matrix Metalloproteinases, Secreted; EC 3.4.24.- / matrix metalloproteinase 19; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


92. Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W, Parker R: In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res; 2006 Aug 1;12(15):4523-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
  • PURPOSE: Drug resistance in malignant gliomas contributes to poor clinical outcomes.
  • We determined the in vitro drug response profiles for 478 biopsy specimens from patients with the following malignant glial histologies: astrocytoma (n = 71), anaplastic astrocytoma (n = 39), glioblastoma multiforme (n = 259), oligodendroglioma (n = 40), and glioma (n = 69).
  • RESULTS: In vitro drug resistance in malignant gliomas was independent of prior therapy.
  • [MeSH-minor] Camptothecin / analogs & derivatives. Camptothecin / pharmacology. Carmustine / pharmacology. Cisplatin / pharmacology. DNA Modification Methylases / drug effects. DNA Modification Methylases / genetics. DNA Repair Enzymes / drug effects. DNA Repair Enzymes / genetics. Dacarbazine / pharmacology. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Glutathione S-Transferase pi / drug effects. Glutathione S-Transferase pi / genetics. Humans. Immunohistochemistry. P-Glycoprotein / drug effects. P-Glycoprotein / genetics. P-Glycoproteins. Paclitaxel / pharmacology. Structure-Activity Relationship. Tumor Suppressor Protein p53 / drug effects. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / drug effects. Tumor Suppressor Proteins / genetics. Vincristine / pharmacology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16899598.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Biomarkers, Tumor; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 5J49Q6B70F / Vincristine; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 6.5.1.- / DNA Repair Enzymes; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


93. Phuphanich S, Carson KA, Grossman SA, Lesser G, Olson J, Mikkelsen T, Desideri S, Fisher JD, New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro Oncol; 2008 Aug;10(4):617-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma.
  • Patients with recurrent malignant glioma received oral atrasentan at >or=10 mg/day.
  • Twenty-two patients had glioblastoma multiforme (GBM), 2 had anaplastic astrocytoma, and 1 had an anaplastic oliogodendroglioma; 24 patients had received one prior chemo therapy regimen before being enrolled in the study.
  • We conclude that the MTD of daily oral atrasentan in patients with recurrent malignant glioma is 70 mg/day.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2006 Jan;8(1):27-37 [16443945.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Br J Clin Pharmacol. 2000 Jun;49(6):562-73 [10848720.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Br J Clin Pharmacol. 2002 Apr;53(4):355-62 [11966665.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27850-5 [12023962.001]
  • [Cites] Nat Rev Drug Discov. 2002 Dec;1(12):986-1001 [12461520.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):679-89 [12586806.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2965-72 [12912943.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4406-11 [15240529.001]
  • [Cites] Cancer Chemother Rep. 1974 Nov-Dec;58(6):787-92 [4447922.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Peptides. 1993 Mar-Apr;14(2):385-99 [8483816.001]
  • [Cites] J Neurochem. 1994 Dec;63(6):2240-7 [7964744.001]
  • [Cites] J Cardiovasc Pharmacol. 1995;26 Suppl 3:S408-11 [8587429.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Feb;276(2):473-81 [8632312.001]
  • [Cites] Biochim Biophys Acta. 1996 May 28;1311(3):155-63 [8664342.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Apr;56(4):435-9 [9100674.001]
  • [Cites] N Engl J Med. 1998 Mar 19;338(12):784-90 [9504938.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]
  • [Cites] Circulation. 1998 Nov 24;98(21):2262-8 [9826312.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):32-40 [15701280.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • (PMID = 18477765.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062406; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01-CA62406; United States / NCI NIH HHS / CA / UO1 CA-62475
  • [Publication-type] Case Reports; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pyrrolidines; V6D7VK2215 / atrasentan
  • [Other-IDs] NLM/ PMC2666236
  •  go-up   go-down


94. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE 2nd, Walker A, Friedman HS: Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol; 2009 Mar 10;27(8):1262-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
  • PURPOSE: This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide.
  • PATIENTS AND METHODS: Patients were accrued into two independent strata on the basis of histology: glioblastoma multiforme (GBM) and anaplastic glioma.
  • One of 34 patients (3%) with GBM (95% CI, 0.1% to 15%) and five of 32 assessable patients (16%) with anaplastic glioma (95% CI, 5% to 33%) were responders.
  • CONCLUSION: O(6)-BG when added to a 1-day dosing regimen of temozolomide was able to restore temozolomide sensitivity in patients with temozolomide-resistant anaplastic glioma, but there seemed to be no significant restoration of temozolomide sensitivity in patients with temozolomide-resistant GBM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Drug Resistance, Neoplasm. Female. Guanine / administration & dosage. Guanine / adverse effects. Guanine / analogs & derivatives. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3522-8 [11032594.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):85-9 [17031555.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1991 Jul 1;51(13):3367-72 [1647266.001]
  • [Cites] Br J Cancer. 1993 Jun;67(6):1299-302 [8512814.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(6):471-6 [8258196.001]
  • [Cites] J Neurooncol. 1994;21(2):135-40 [7861189.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 [7659775.001]
  • [Cites] Br J Cancer. 1996 Feb;73(4):482-90 [8595163.001]
  • [Cites] Br J Cancer. 1996 May;73(9):1049-52 [8624262.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1030-6 [8855970.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3310-5 [9779706.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):735-41 [9816224.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3851-7 [9850030.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7178-87 [16192602.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7646-53 [16234526.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):399-404 [17264335.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • (PMID = 19204199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCI NIH HHS / CA / R37 CA 011898-38; United States / NCI NIH HHS / CA / R21 CA101298; United States / NINDS NIH HHS / NS / 5P50 NS20023-25; United States / NCI NIH HHS / CA / 5P50 CA 108786-4; United States / NCRR NIH HHS / RR / RR024126; United States / NCI NIH HHS / CA / 1 R21 CA 101298-01; United States / NCRR NIH HHS / RR / TL1 RR024126; United States / NCI NIH HHS / CA / R37 CA011898
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 01KC87F8FE / O(6)-benzylguanine; 5Z93L87A1R / Guanine; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  • [Other-IDs] NLM/ PMC2667825
  •  go-up   go-down


95. Borgmann A, Zinn C, Hartmann R, Herold R, Kaatsch P, Escherich G, Möricke A, Henze G, von Stackelberg A, ALL-REZ BFM Study Group: Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer; 2008 Jan;44(2):257-68

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.
  • PURPOSE: To investigate the cumulative incidence of and the risk factors for developing second malignant neoplasms (SMN) in children and adolescents following treatment for relapse of acute lymphocytic leukaemia (ALL).
  • RESULTS: Out of the 1376 patients 21 were diagnosed with SMN including non-lymphoblastic leukaemia/myelodysplastic syndrome (n=6), osteo-/Ewing's-/fibroblastic sarcoma (n=4), B-cell ALL/lymphoma (n=2), thyroid carcinoma (n=2), basal cell carcinoma, adeno carcinoma, squamous cell carcinoma, meningioma, malignant histiocytosis, glioblastoma and anaplastic astrocytoma (n=1 each).
  • Compared to the incidence of neoplasm in the age-matched population, there was a 10-fold increase of neoplasia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981026.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Mertens R; Imbach P; Pongratz E; Rupprecht T; Henze G; Wickmann L; Otte J; Bode U; Eberl W; Pekrun A; Kirschstein M; Hofmann K; Frank R; Möbius D; Andler W; Niekrens C; Breu H; Suttorp M; Göbel U; Weinmann G; Sauerbrey A; Beck JF; Janka-Schaub G; Welte K; Kulozik A; Tautz C; Graf N; Fink FM; Zintl F; Hermann J; Rupprath G; Dupuis W; Rodehüser M; Schrappe M; Berthold F; Sternschulte W; Körholz D; Schmitt K; Selle B; Gutjahr P; Dürken M; Christiansen H; Rose M; Borkhardt A; Burdach S; Jürgens H; Scheurlen W; Eggers G; Geib R; Dickerhoff R; Bielack S; Rauh W; Niethammer D; Debatin KM; Gadner H; Dohrn B; Schlegel PG; Niggli F
  •  go-up   go-down


96. Fiorentini G, Giovanis P, Rossi S, Dentico P, Paola R, Turrisi G, Bernardeschi P: A phase II clinical study on relapsed malignant gliomas treated with electro-hyperthermia. In Vivo; 2006 Nov-Dec;20(6A):721-4
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II clinical study on relapsed malignant gliomas treated with electro-hyperthermia.
  • The purpose of this study was to evaluate the activity and toxicity of electro-hyperthermia (ET) on relapsed malignant glioma patients.
  • Twelve patients with histologically diagnosed malignant glioma entered the study.
  • Eight patients had glioblastoma multiforme, two had anaplastic astrocytoma grade III and two had anaplastic oligodendroglioma.
  • ET appears to have some effectiveness in adults with relapsed malignant glioma.
  • [MeSH-major] Brain Neoplasms / therapy. Electric Stimulation Therapy. Glioma / therapy. Hyperthermia, Induced. Neoplasm Recurrence, Local / therapy

  • Genetic Alliance. consumer health - Malignant hyperthermia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203754.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


97. Reardon DA, Quinn JA, Rich JN, Desjardins A, Vredenburgh J, Gururangan S, Sathornsumetee S, Badruddoja M, McLendon R, Provenzale J, Herndon JE 2nd, Dowell JM, Burkart JL, Newton HB, Friedman AH, Friedman HS: Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer; 2005 Oct 1;104(7):1478-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
  • BACKGROUND: The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG).
  • Ninety-one patients (85%) had recurrent glioblastoma multiforme (GBM) and 16 (15%) had recurrent anaplastic glioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16088964.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P20 CA096890; United States / NCI NIH HHS / CA / CA11898; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


98. Low SE, Stafford JS: Malignant histiocytosis: a case report of a rare tumour presenting with spontaneous splenic rupture. J Clin Pathol; 2006 Jul;59(7):770-2
Genetic Alliance. consumer health - Histiocytosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant histiocytosis: a case report of a rare tumour presenting with spontaneous splenic rupture.
  • Malignant histiocytosis is a rare invasive proliferation of neoplastic histiocytes.
  • Cases previously reported as malignant histiocytosis were shown to be lymphomas of T or B lineage, especially anaplastic large-cell lymphomas.
  • A case of malignant histiocytosis is described, in which a patient presenting with symptoms suggestive of pneumonia suddenly deteriorated and died.
  • This is the second reported case of malignant histiocytosis presenting with spontaneous splenic rupture.
  • [MeSH-minor] Fatal Outcome. Female. Humans. Liver / pathology. Middle Aged. Neoplasm Invasiveness. Rupture, Spontaneous / etiology. Spleen / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1985 Sep;9(9):905-20 [3905564.001]
  • [Cites] J Pathol. 1990 Jan;160(1):9-17 [2156039.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):530-6 [2194647.001]
  • [Cites] Med Pediatr Oncol. 1995 Jul;25(1):1-7 [7752995.001]
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1386-92 [9808131.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1372-9 [11684953.001]
  • [Cites] Pathol Annu. 1985;20 Pt 2:1-28 [3892461.001]
  • [Cites] Histopathology. 2002 Jul;41(1):1-29 [12121233.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):258-65 [12548175.001]
  • [Cites] Br J Cancer. 1970 Dec;24(4):687-95 [4926535.001]
  • [Cites] J Clin Pathol. 1983 May;36(5):559-65 [6573336.001]
  • [Cites] Blood. 1984 Jul;64(1):48-53 [6610448.001]
  • [Cites] J R Coll Surg Edinb. 2002 Feb;47(1):437-45 [11874265.001]
  • (PMID = 16803951.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860417
  •  go-up   go-down


99. De Simone P, Gelin M, El Nakadi I: Amelanotic malignant melanoma of the esophagus. Report of a case. Minerva Chir; 2006 Feb;61(1):45-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amelanotic malignant melanoma of the esophagus. Report of a case.
  • Primary malignant melanomas of the esophagus are rare neoplasms with aggressive behavior and tendency to lymphatic and hematogenous spread.
  • The esophageal neoplasm was treated by subtotal esophagectomy while the squamous cell carcinoma of the epiglottis was referred to radiotherapy 1 month after surgery.
  • Microscopy showed diffuse proliferation of anaplastic cells with multiple mitotic figures, marked nuclei and multilobulated nucleoli.
  • The neoplasm stained positive for HBM-45 antigen and S-100 protein.
  • Review of patient's medical history and exploration of skin and mucous membranes failed to reveal malignant lesions and definitive diagnosis was primary amelanotic malignant melanoma of the esophagus.
  • In conclusion the present case confirms that primary malignant melanomas of the esophagus have a dismal outcome even in cases of early-stage lesions amenable to surgical resection.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16568022.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


100. Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M, Wen PY: Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol; 2007 Jul;9(3):354-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
  • This phase II study evaluated the feasibility of this antiangiogenic chemotherapy regimen in adults with recurrent malignant gliomas.
  • The regimen consisted of low-dose etoposide (35 mg/m2 [maximum, 100 mg/day] daily for 21 days), alternating every 21 days with cyclophosphamide (2 mg/kg [maximum, 100 mg/day] daily for 21 days), in combination with daily thalidomide and celecoxib, in adult patients with recurrent malignant gliomas.
  • Twenty-eight patients had glioblastoma multiforme (GBMs), and 20 had anaplastic gliomas (AGs).
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2299-304 [12805330.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6624-8 [11559524.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:169-77 [14531575.001]
  • [Cites] Mol Cancer Res. 2003 Oct;1(12):863-70 [14573787.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12917-22 [14561896.001]
  • [Cites] Semin Oncol. 1997 Apr;24(2):203-18 [9129690.001]
  • [Cites] Neurosurgery. 1997 May;40(5):1027-33 [9149261.001]
  • [Cites] Pathol Oncol Res. 1998;4(1):62-75 [9555124.001]
  • [Cites] Acta Neuropathol. 1999 Sep;98(3):240-4 [10483780.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4574-7 [10493510.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):31-40 [15565458.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):295-9 [15735920.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Curr Neurol Neurosci Rep. 2005 May;5(3):186-97 [15865884.001]
  • [Cites] Curr Oncol Rep. 2004 Jan;6(1):49-52 [14664761.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2030-8 [15026340.001]
  • [Cites] Blood. 2004 May 1;103(9):3549-51 [14726401.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 7):2-11 [15179620.001]
  • [Cites] Biomed Pharmacother. 2004 Oct;58(8):447-50 [15464874.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer. 1992 Dec 1;70(11):2673-80 [1423198.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5 [7513432.001]
  • [Cites] Glia. 1995 Nov;15(3):339-47 [8586468.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] J Neurooncol. 1996 Feb;27(2):149-55 [8699237.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1877-84 [8656256.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):187-92 [8996141.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):213-9 [11957147.001]
  • [Cites] FASEB J. 2002 May;16(7):681-90 [11978732.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2731-5 [12019144.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):60-5 [12506171.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1566-72 [12684433.001]
  • [Cites] J Cell Biochem. 2005 Sep 1;96(1):16-24 [16052525.001]
  • [Cites] Mol Ther. 2005 Nov;12(5):778-88 [16150649.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Nov;27(11):573-81 [16282886.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):327-34 [16195797.001]
  • [Cites] Int J Oncol. 2006 Jan;28(1):53-9 [16327979.001]
  • [Cites] Oncol Rep. 2006 Jul;16(1):33-9 [16786120.001]
  • [Cites] Oncol Rep. 2006 Jul;16(1):133-40 [16786136.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):281-93 [16554966.001]
  • [Cites] J Neurooncol. 2006 Dec;80(3):313-32 [16807780.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):31-8 [11763420.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Am J Hematol. 2000 Jan;63(1):35-7 [10602166.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • [Cites] Am J Kidney Dis. 2000 Mar;35(3):539-43 [10692284.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):R15-24 [10772661.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4152-60 [10945623.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4926-31 [10987308.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1195-206 [11181686.001]
  • [Cites] J Exp Med. 2001 Mar 5;193(5):607-20 [11238591.001]
  • [Cites] J Neurooncol. 2001 Jan;51(1):41-5 [11349879.001]
  • [Cites] N Engl J Med. 2001 Jun 21;344(25):1951-2 [11419443.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1041-7 [11533708.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4342-6 [12907602.001]
  • (PMID = 17452651.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; 4Z8R6ORS6L / Thalidomide; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; JCX84Q7J1L / Celecoxib
  • [Other-IDs] NLM/ PMC1907419
  •  go-up   go-down






Advertisement